Information on EC 1.5.1.3 - dihydrofolate reductase

New: Word Map on EC 1.5.1.3
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY
1.5.1.3
-
RECOMMENDED NAME
GeneOntology No.
dihydrofolate reductase
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
kinetic mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
rapid equilibrium random mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
catalytic mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
catalytic mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
catalytic mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
catalytic mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
catalytic mechanism
vertebrata, protozoa
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
bifunctional proteins with DHFR and thymidylate synthase activity
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
pteridine-binding site
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
rapid random equilibrium mechanism with NADPH and reduced acetylpyridine adenine nucleotide as cofactor
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
cofactor binding mechanism, pH-dependence investigation
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
inhibitor binding mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
inhibitor binding mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
inhibitor binding mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
inhibitor binding mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
inhibitor binding mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
inhibitor binding mechanism
Pigeon
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
inhibitor binding mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
substrate and cofactor binding mechanism
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
substrate and antifolate inhibitor methotrexate binding, modeling of three-dimensional structure
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
analysis of higher energy conformational substates by NMR relaxation dispersion. The maximum hydride transfer and steady-state turnover rates are governed by the dynamics of transitions between ground and excited states of the intermediates. Model of conformational changes during the catalytic cycle
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
donor carbon at the hydride transfer transition state resembles the reactant state more than the product state, whereas the acceptor carbon is more productlike, a symptom of transition state imbalance
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
kinetic isotope effect analysis, enzyme requires no no donor-acceptor distance fluctuations and thus no gating
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
model for hydrogen transfer includes contributions from quantum mechanical tunnelling coupled with protein motions that actively modulate the tunnelling distance
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
ordered kinetic mechanism at elevated temperature around 60C, with NADPH binding first. More random mechanism at temperatures around 20C with greatly reduced Km-value for 7,8-dihydrofolate. Rate-limiting hydride-transfer with a moderate enthalpy of activiation
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
study on enzyme ternary complex with substrate analogue folates and oxidized NADP+ cofactor using NMR relaxation methods. Conformational exchanges of protein between a ground state with closed conformation of active site loops and an excited state with loops in occluded conformation. Fluctuations include motions of the nicotinamide ring of the cofactor into and out of the active site
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
binding of NADPH is accompanied by release of 38 water molecules, while binding of dihydrofolate is accompanied by the net uptake of water
P00383
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
in Plasmodium bifunctional thymidylate synthase-dihydrofolate reductase, the overall rate-limiting step is thymidylate synthase catalysis.If thymidylate synthase is in an activated liganded conformation, the dihydrofolate reductase is 2-fold activated. The thymidylate synthase rate is also reciprocally activated by 1.5-fold if dihydrolfolate reductase is in an activated, ligand-bound conformation
P13922
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
the active-site loop dynamics access a closed conformation, and the accompanying closed to occluded rate constant is comparable to the maximum pH-independent hydride transfer rate constant. The closed to occluded conformational transition in the product ternary complex is a prerequisite for progression through the catalytic cycle. The rate of this process places an effective limit on the maximum rate of the hydride transfer step. The dynamics of the C-terminally associated region is pH-dependent, but the dynamics of the active-site loops and cofactor binding cleft are pH-independent
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
Ala16, Ile51, Cys59, Ser108 and Ile164 are active site residues
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
Ala16, Ile51, Cys59, Ser108 and Ile164 are active site residues, catalytic mechanism, overview
-
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+
show the reaction diagram
the product (tetrahydrofolate) dissociation step that is the rate-limiting step in Escherichia coli DHFR is significantly accelerated in spDHFR so that hydride transfer or a preceding step is rate-limiting
Q54801
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
reduction
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Folate biosynthesis
-
-
folate transformations II
-
-
Metabolic pathways
-
-
N10-formyl-tetrahydrofolate biosynthesis
-
-
One carbon pool by folate
-
-
sulfopterin metabolism
-
-
tetrahydrofolate biosynthesis
-
-
tetrahydrofolate metabolism
-
-
SYSTEMATIC NAME
IUBMB Comments
5,6,7,8-tetrahydrofolate:NADP+ oxidoreductase
The enzyme from animals and some micro-organisms also slowly reduces folate to 5,6,7,8-tetrahydrofolate.
SYNONYMS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase
-
-
7,8-dihydrofolate reductase
-
-
-
-
dehydrogenase, tetrahydrofolate
-
-
-
-
DHFR
-
-
-
-
DHFR
J7GQW2
-
DHFR
Q6FPH0
-
DHFR
Q6IQS4
-
DHFR
P15093
-
DHFR
Haloferax volcanii DSM 3757
P15093
-
-
DHFR
-
-
DHFR
O30463
-
DHFR type IIIC
-
-
-
-
DHFR-TS
B5U9U8
-
dihydrofolate reductase
-
-
dihydrofolate reductase
-
-
dihydrofolate reductase
-
-
dihydrofolate reductase
D1MX72
-
dihydrofolate reductase
D1MX71
-
dihydrofolate reductase
-
-
dihydrofolate reductase
D1MX70
-
dihydrofolate reductase
-
-
dihydrofolate reductase
D1MYR1
-
dihydrofolate reductase
-
-
dihydrofolate reductase
-
-
dihydrofolate reductase
-
-
dihydrofolate reductase
-
-
dihydrofolate reductase-thymidylate synthase
-
-
-
-
dihydrofolate reductase-thymidylate synthase
B5U9U8
-
dihydrofolate reductase:thymidylate synthase
-
-
-
-
dihydrofolic acid reductase
-
-
-
-
dihydrofolic reductase
-
-
-
-
EC 1.5.1.4
-
-
formerly
-
folA3
AB986558
gene name
folA3
Haloarcula japonica TR-1
AB986558
gene name
-
folic acid reductase
-
-
-
-
folic reductase
-
-
-
-
HjDHFR
AB986558
-
HjDHFR
Haloarcula japonica TR-1
AB986558
-
-
mjDHFR
D1MX72
-
myDHFR
D1MX71
-
NADPH-dihydrofolate reductase
-
-
-
-
pteridine reductase:dihydrofolate reductase
-
-
-
-
R-plasmid-encoded dihydrofolate reductase
P00383
-
R67 DHFR
P00383
-
R67 dihydrofolate reductase
P00383
-
reductase, dihydrofolate
-
-
-
-
S3DHFR
Staphylococcus aureus CM.S2
-
-
-
svDHFR
D1MYR1
-
tetrahydrofolate dehydrogenase
-
-
-
-
thymidylate synthase-dihydrofolate reductase
-
bifunctional enzyme
thymidylate synthetase-dihydrofolate reductase
-
-
-
-
Trimethoprim resistance protein
-
-
-
-
TS-DHFR
-
bifunctional enzyme
CAS REGISTRY NUMBER
COMMENTARY
9002-03-3
-
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
green algae, thymidylate synthase and dihydrofolate reductase cannot be dissociated from each other
-
-
Manually annotated by BRENDA team
gene dhfr-ts
UniProt
Manually annotated by BRENDA team
expression in Escherichia coli; strain C-125
-
-
Manually annotated by BRENDA team
overview
-
-
Manually annotated by BRENDA team
2 forms
-
-
Manually annotated by BRENDA team
overview
-
-
Manually annotated by BRENDA team
trimethoprim-susceptible strain PC 174 and trimethoprim-resistant strain PC 178
-
-
Manually annotated by BRENDA team
chinese hamster, methotrexate-sensitive and methotrexate-resistant cells
-
-
Manually annotated by BRENDA team
2 forms: I, II; baby hamster kidney cells
-
-
Manually annotated by BRENDA team
baby hamster kidney cells
-
-
Manually annotated by BRENDA team
wild type and methotrexate-resistant
-
-
Manually annotated by BRENDA team
bifunctional enzyme: dihydrofolate reductase-thymidylate synthase EC 2.1.1.45
-
-
Manually annotated by BRENDA team
bifunctional enzyme: pteridine reductase-dihydrofolate reductase
-
-
Manually annotated by BRENDA team
three different forms I, IIa and IIb
-
-
Manually annotated by BRENDA team
wild carrot, enzyme complex with dihydrofolate reductase activity, thymidylate synthase activity and three other polypeptides of unknown function
-
-
Manually annotated by BRENDA team
expression in Chinese hamster ovary cells
Uniprot
Manually annotated by BRENDA team
R-plasmid encoded, trimethoprim-resistant
-
-
Manually annotated by BRENDA team
Enterococcus faecalis R
R
-
-
Manually annotated by BRENDA team
2 forms termed mutant type and wild-type enzyme in a single organism; amethopterin-resistant strain; strain A, var. durans
-
-
Manually annotated by BRENDA team
amethopterin-resistant strain
-
-
Manually annotated by BRENDA team
Enterococcus faecium A
strain A, var. durans
-
-
Manually annotated by BRENDA team
amethopterin-resistant
-
-
Manually annotated by BRENDA team
isoenzymes type I and type II, resistant to trimethoprim
-
-
Manually annotated by BRENDA team
isozyme type II, R-plasmid encoded isoform R67
UniProt
Manually annotated by BRENDA team
isozyme type II, R-plasmid encoded; trimethoprim-resistant strain
-
-
Manually annotated by BRENDA team
methotrexate-resistant mutant; strain MB 1428, B
-
-
Manually annotated by BRENDA team
plasmid-encoded isoform R67
-
-
Manually annotated by BRENDA team
plasmid-encoded isoform R67
UniProt
Manually annotated by BRENDA team
plasmid-encoded R67 isoform
UniProt
Manually annotated by BRENDA team
seleno- and telluromethionine-containing enzyme
Uniprot
Manually annotated by BRENDA team
strain B ATCC 11303; strain MB 1428, B
-
-
Manually annotated by BRENDA team
strain MB 1428, B
-
-
Manually annotated by BRENDA team
strains: MB3746, MB 3747 of K12; trimethoprim-resistant strain
-
-
Manually annotated by BRENDA team
trimethoprim-resistant strain
-
-
Manually annotated by BRENDA team
various strains
-
-
Manually annotated by BRENDA team
wild-type and mutants
-
-
Manually annotated by BRENDA team
Escherichia coli MB 1428
strain MB 1428, B
-
-
Manually annotated by BRENDA team
overview
-
-
Manually annotated by BRENDA team
-
AB986558
GenBank
Manually annotated by BRENDA team
Haloarcula japonica TR-1
-
AB986558
GenBank
Manually annotated by BRENDA team
extremely halophilic archaebacterium
-
-
Manually annotated by BRENDA team
extremely halophilic archaebacterium; isozyme hDHFR-1 from gene hdrA and isozyme hDHFR-2 from gene hdrB
-
-
Manually annotated by BRENDA team
Haloferax volcanii DSM 3757
-
SwissProt
Manually annotated by BRENDA team
i.e. Helicoverpa virescens, tobacco budworm
-
-
Manually annotated by BRENDA team
c.86 + 60_78 insertion/deletion polymorphism is associated with serum and red blood cell folate concentrations in women
-
-
Manually annotated by BRENDA team
cancer patients with and without thrombosis
-
-
Manually annotated by BRENDA team
children with acute lymphoblastic leukemia
-
-
Manually annotated by BRENDA team
cultured mammalian cells, overview
-
-
Manually annotated by BRENDA team
methotrexate-resistant WIL-2 lymphoblastoid cells
-
-
Manually annotated by BRENDA team
methotrexate-resistant WIL-2 lymphoblastoid cells; methotrexate-sensitive cell line HeLa BU-25, methotrexate-insensitive cell line VA2-B
-
-
Manually annotated by BRENDA team
mothers of a spina bifida affected child, spina biWda patients, and controls
-
-
Manually annotated by BRENDA team
patients with osteosarcoma
-
-
Manually annotated by BRENDA team
human virus produced in cultured lymphoma derived B-cells
-
-
Manually annotated by BRENDA team
amethopterin-resistant
-
-
Manually annotated by BRENDA team
amethopterin-resistant; isozymes I and II
-
-
Manually annotated by BRENDA team
amethopterin-resistant; methotrexate-resistant
-
-
Manually annotated by BRENDA team
antifolate-resistant strain
-
-
Manually annotated by BRENDA team
methotrexate-resistant
-
-
Manually annotated by BRENDA team
bifunctional enzyme dihydrofolate reductase-thymidylate synthase
-
-
Manually annotated by BRENDA team
bifunctional enzyme dihydrofolate reductase-thymidylate synthase; methotrexate-resistant strain with altered enzyme
-
-
Manually annotated by BRENDA team
methotrexate resistant bifunctional enzyme: thymidylate synthase-dihydrofolate reductase
-
-
Manually annotated by BRENDA team
cultured mammalian cells, overview
-
-
Manually annotated by BRENDA team
sp. nov.
Uniprot
Manually annotated by BRENDA team
altered enzyme encoded by amplified genes in cultured fibroblasts
-
-
Manually annotated by BRENDA team
L1210 lymphoma cells
-
-
Manually annotated by BRENDA team
L1210 lymphoma cells, amethopterin-resistant
-
-
Manually annotated by BRENDA team
multiple forms
-
-
Manually annotated by BRENDA team
overview
-
-
Manually annotated by BRENDA team
2 forms, not genetically determined isozymes
-
-
Manually annotated by BRENDA team
Pigeon
-
-
-
Manually annotated by BRENDA team
Pigeon
overview
-
-
Manually annotated by BRENDA team
bifunctional enzyme: dihydrofolate reductase-thymidylate synthase EC 2.1.1.45
-
-
Manually annotated by BRENDA team
pyrimethamine-sensitive and pyrimethamine-resistant strain
-
-
Manually annotated by BRENDA team
bifunctional thymidylate synthase-dihydrofolate reductase
Uniprot
Manually annotated by BRENDA team
isolated from infected Kenyan adults
-
-
Manually annotated by BRENDA team
isolated from Sudanese patients treated with sulphadoxine/pyrimethamine or sulphadoxine/pyrimethamine plus chloroquine
-
-
Manually annotated by BRENDA team
isolates from Car Nicobar Island, India
-
-
Manually annotated by BRENDA team
isolates from Cote d'Ivoire
-
-
Manually annotated by BRENDA team
isolates from Malawi
-
-
Manually annotated by BRENDA team
isolates from Mozambique
-
-
Manually annotated by BRENDA team
isolates from southern Mozambique
-
-
Manually annotated by BRENDA team
several Ser108 mutants
-
-
Manually annotated by BRENDA team
bifunctional dihydrofolate reductase/thymidylate synthase
-
-
Manually annotated by BRENDA team
fragment; bifunctional dihydrofolate reductase-thymidylate synthase
UniProt
Manually annotated by BRENDA team
isolates from Sri Lanka
-
-
Manually annotated by BRENDA team
polymorphisms in Indian field isolates
-
-
Manually annotated by BRENDA team
wild-type and mutant enzymes recombinant from Escherichia coli
-
-
Manually annotated by BRENDA team
human-derived
-
-
Manually annotated by BRENDA team
rat-derived
-
-
Manually annotated by BRENDA team
recombinant human-derived and rat-derived enzyme
-
-
Manually annotated by BRENDA team
protozoa
-
-
-
Manually annotated by BRENDA team
protozoa
overview
-
-
Manually annotated by BRENDA team
carcinoma Walker 256
-
-
Manually annotated by BRENDA team
phage type 179, R-plasmid enzyme, isozyme type III
-
-
Manually annotated by BRENDA team
methicillin-sensitive and -resistant strains
-
-
Manually annotated by BRENDA team
strain CM.S2, trimethoprim-resistant enzyme
-
-
Manually annotated by BRENDA team
Staphylococcus aureus CM.S2
strain CM.S2, trimethoprim-resistant enzyme
-
-
Manually annotated by BRENDA team
methicillin-sensitive and -resistant strains
-
-
Manually annotated by BRENDA team
methicillin-sensitive and -resistant strains
-
-
Manually annotated by BRENDA team
methotrexate-resistant form
-
-
Manually annotated by BRENDA team
wild-type and mutant forms
-
-
Manually annotated by BRENDA team
overview
-
-
Manually annotated by BRENDA team
thermophilic bacterium
-
-
Manually annotated by BRENDA team
bifunctional dihydrofolate reductase-thymidylate synthase
-
-
Manually annotated by BRENDA team
bifuntional enzyme with dihydrofolate reductase and thymidylate synthase activity; trimethoprim-resistant strain
-
-
Manually annotated by BRENDA team
overview
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
P13955
inhibition of DHFR leads to the depletion of tetrahydrofolate and eventual cell death
malfunction
-
inhibition of the enzyme activity leads to arrest of DNA synthesis and hence cell death
malfunction
P13955
inhibitor trimethoprim shows loss potency and NADPH synergy on binding S1 mutant DHFR. Mutation of residues Y98F/A43G in S1 mutant restores trimethoprim sensitivity and NADPH synergy
malfunction
-
enzyme knockdown results in the abnormal developments of zebrafish embryos in the early stages. Obvious malformations in heart and outflow tract are also observed in knockdown embryos. Enzyme knockdown causes reduced cell proliferation and increased apoptosis
metabolism
P13955
DHFR is a critical enzyme in the maintenance of reduced folate pools used in the biosynthetic pathways of purines, thymidylate, methionine, glycine, pantothenic acid, and N-formyl-methionyl tRNA
physiological function
-
DHFR is essential for the survival and pathogenesis of anthrax. DHFR is required for de novo DNA synthesis and amino acid synthesis
physiological function
P13955
DHFR is the enzyme responsible for the NADPH-dependent reduction of 5,6-dihydrofolate to 5,6,7,8-tetrahydrofolate, an essential cofactor in the synthesis of purines, thymidylate, methionine, and other key metabolites. DHFR is a critical enzyme in the maintenance of reduced folate pools used in the biosynthetic pathways of purines, thymidylate, methionine, glycine, pantothenic acid, and N-formyl-methionyl tRNA
physiological function
-
dihydrofolate reductase is an enzyme with a pivotal role in the synthesis of intracellular tetrahydrofolic acid, which is essential in the synthesis of purines, some amino acids, and thymidine. DHFR is the sole source of tetrahydrofolic acid
physiological function
-
tetrahydrofolate is a precursor of cofactors necessary for the synthesis of thymidylate, purine nucleotides,methionine, serine, and glycine required for DNA, RNA, and protein synthesis
physiological function
-
dihydrofolate reductase is required for the development of heart and outflow tract in zebrafish. Enzyme overexpression promotes cell proliferation and inhibited apoptosis
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
6-hydroxymethylpterin + NADPH
6-hydroxymethyl-7,8-dihydropterin + NADP+
show the reaction diagram
-
-
-
-
?
6-methylpterin + NADPH
6-methyl-7,8-dihydropterin + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + acetylpyridine adenine nucleotide, reduced
5,6,7,8-tetrahydrofolate + acetylpyridine adenine nucleotide, oxidized
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADH + H+
5,6,7,8-tetrahydrofolate + NAD+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADP + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADP + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
assay at 37C
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
P17719
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
ir
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
ir
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
-
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
ir
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
-
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Pigeon
-
-
-
-
-
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Pigeon
-
-
-
-
ir
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
-
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
-
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
ir
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
-
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
P13922
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
ir
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Q70YQ6
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
protozoa
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
protozoa
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
P0ABQ4
kinetic mechanism
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
strongly specific for
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
bifunctional enzyme DHFR-thymidylate synthase
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium constant: 320000000000
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
at neutral pH the forward reaction is favored
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
?, r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
?, r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
equilibrium strongly favors tetrahydrofolate production
-
?, r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
enzyme content of methotrexate-insensitive cell line VA2-B is 200fold higher than that of sensitive cell line HeLa BU-25 due to production of alternate enzyme type
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
enzyme plays important role in nucleotide biosynthesis
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
reverse reaction at only one tenth of forward reaction
-
r
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
maintainance of adequate levels of fully reduced folate in metabolism of proliferating cells
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
maintainance of adequate levels of fully reduced folate in metabolism of proliferating cells
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
maintainance of adequate levels of fully reduced folate in metabolism of proliferating cells
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
key enzyme in biosynthesis of purines, pyrimidines and several amino acids
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
key role in thymidylate biosynthesis
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
DHFR activity is not essential for virus replication
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
directly correlated with thymidylate synthesis
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
at pH 7 hydride transfer is at least partially rate limiting for temperatures below 50C, at higher temperatures hydride transfer is faster than the steady state
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
cannot use NADH as reducing agent
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
clear evidence against dihydrofolate substrate channeling in the bifunctional thymidylate synthase-dihydrofolate reductase
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
P00378
water can serve as the Bronsted acid for the protonation of N5 of dihydrofolate during DHFR catalyzed reduction
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Staphylococcus aureus CM.S2
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Enterococcus faecalis R
-
-
-
-
ir
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Enterococcus faecium A
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
O30463
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Q27793
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
r
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Q6IQS4
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
P00383
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
B5U9U8
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Q6FPH0
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Q2YY41
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
P13955
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
J7GQW2
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
the reaction is essential in DNA synthesis
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
DHFR catalyzes hydride transfer from the cofactor NADPH to 7,8-dihydrofolate to produce tetrahydrofolate requiring electrostatic complementarity between the enzyme and the transition state
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
P0A017
the conserved residues Leu28, Val31, Ile50 and Leu54 forming a hydrophobic pocket in the enzyme are the binding site for the p-aminobenzamide moiety of the substrate dihydrofolate
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
8-methylpterin + NADPH
8-methyl-7,8-dihydropterin + NADP+
show the reaction diagram
-
-
subsequently reduced more slowly and incompletely to 8-methyl-5,6,7,8-tetrahydropterin
?
D-erythro-7,8-neopterin + NADPH
?
show the reaction diagram
-
low activity
-
-
?
D-threo-neopterin + NADPH
?
show the reaction diagram
-
low activity
-
-
?
dihydrobiopterin + NADPH
? + NADP+
show the reaction diagram
-
10% of the activity with 7,8-dihydrofolate
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
r
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
Q54801
-
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
D1MYR1
-
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
D1MX70
-
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
D1MX71
-
-
-
?
dihydrofolate + NADPH + H+
tetrahydrofolate + NADP+
show the reaction diagram
D1MX72
-
-
-
?
dihydropteroate + NADPH
?
show the reaction diagram
-
-
-
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
-
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
-
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
no activity
-
-
-
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
no activity
-
-
-
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
no activity
-
-
-
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
no activity
-
-
-
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
no activity
-
-
-
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
no activity
-
-
-
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
slow rate
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
slow rate
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
slow rate, bifunctional enzyme DHFR-thymidylate synthase
-
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
at a slow rate, reaction not catalyzed by all dihydrofolate reductases
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
activity only at acidic pH around 4.5
-
?
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Enterococcus faecium A
-
-
-
-
-
folate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Escherichia coli MB 1428
-
no activity
-
-
-
L-erythro-neopterin + NADPH
?
show the reaction diagram
-
-
-
-
?
L-threo-7,8-dihydroneopterin + NADPH
?
show the reaction diagram
-
low activity
-
-
?
pterin + NADPH
7,8-dihydropterin + NADP+
show the reaction diagram
-
low activity
-
-
?
xanthopterin + NADPH
?
show the reaction diagram
-
low activity
-
-
?
L-threo-neopterin + NADPH
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
-
-
-
-
-
additional information
?
-
-
-
-
-
-
additional information
?
-
-
equilibrium strongly favors tetrahydrofolate production
-
-
-
additional information
?
-
-
3-acetylpyridine adenine dinucleotide + dihydrofolate: rapid equilibrium random mechanism
-
-
-
additional information
?
-
-
no activity with pterins
-
-
-
additional information
?
-
-
no activity with 7,8-dihydrobiopterin and biopterin
-
-
-
additional information
?
-
-
no activity with folate, sepiapterin, isoxanthopterin, leucopterin
-
-
-
additional information
?
-
-
NADPH + dihydrofolate: steady-state random mechanism
-
-
-
additional information
?
-
-
assay method development
-
-
-
additional information
?
-
-
key enzyme in the biosynthesis of purines, pyrimidines and several amino acids
-
-
-
additional information
?
-
-
key enzyme in the biosynthesis of purines, pyrimidines and several amino acids
-
-
-
additional information
?
-
-
dihydrofolate reductase deficient mutant needs thymidine for growth, pathway overview, knockout mutants with either no pteridine reductase or dihydrofolate reductase activity revealed in comparison to wild-type that 90% of the cellular dihydrofolate reduction activity belongs to DHFR and 10% of the cellular dihydrofolate reductase activity belongs to pteridine reductase
-
-
-
additional information
?
-
-
both dihydrolfolate reductase and thymidylate synthase are substrates for UBC9-catalyzed modification with small ubiquitin-like modifier-1
-
-
-
additional information
?
-
-
dihydrofolate reductase is a substrate of ubiquitin ligase MDM2. MDM2 binds directly to dihydrofolate reductase and catalyzes its monoubiquitination. It reduces dihydrofolate reductase activity in a p53-independent manner, but has no effect on the steady-state level of expression. the ability of MDM2 to inhibit dihydrofolate reductase deoends on an active MDM2 RING-finger domain
-
-
-
additional information
?
-
-
enzyme activity decreases with increasing pressure. The Km values for dihydrofolate and NADPH are slightly higher at 200 MPa than at atmospheric pressure. The hydride transfer step is insensitive to pressure, while the dissociation constants of substrates and cofactors increase with pressure
-
-
-
additional information
?
-
-
free energy perturbation with molecular dynamics simulations of dihydrofolate reductase in complex with dihydrofolate. In the Michaelis complex the pKa is modulated by the Met20 loop fluctuations, providing the largest pKa shift in substates with a tightly closed loop conformation, in the partially closed/open substates, the pKa is similar to that in the occluded complex. Conducive to the protonation, tightly closing the Met20 loop enhances the interactions of the cofactor and the substrate with the Met20 side chain and aligns the nicotinamide ring of the cofactor coplanar with the pterin ring of the substrate
-
-
-
additional information
?
-
-
in Cryptosporidium, DHFR and thymidylate synthase are present as a bifunctional enzyme, DHFR-TS
-
-
-
additional information
?
-
B5U9U8
a bifunctional enzyme with dihydrofolate reductase and thymidylate synthase activities, overview
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
7,8-dihydrofolate + NADH + H+
5,6,7,8-tetrahydrofolate + NAD+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
maintainance of adequate levels of fully reduced folate in metabolism of proliferating cells
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
maintainance of adequate levels of fully reduced folate in metabolism of proliferating cells
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
maintainance of adequate levels of fully reduced folate in metabolism of proliferating cells
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
key enzyme in biosynthesis of purines, pyrimidines and several amino acids
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
key role in thymidylate biosynthesis
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
DHFR activity is not essential for virus replication
-
-
?
7,8-dihydrofolate + NADPH
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
directly correlated with thymidylate synthesis
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
r
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
P00383
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
B5U9U8
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Q6FPH0
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
Q2YY41
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
P13955
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
J7GQW2
-
-
-
?
7,8-dihydrofolate + NADPH + H+
5,6,7,8-tetrahydrofolate + NADP+
show the reaction diagram
-
the reaction is essential in DNA synthesis
-
-
?
additional information
?
-
-
key enzyme in the biosynthesis of purines, pyrimidines and several amino acids
-
-
-
additional information
?
-
-
key enzyme in the biosynthesis of purines, pyrimidines and several amino acids
-
-
-
additional information
?
-
-
dihydrofolate reductase deficient mutant needs thymidine for growth, pathway overview, knockout mutants with either no pteridine reductase or dihydrofolate reductase activity revealed in comparison to wild-type that 90% of the cellular dihydrofolate reduction activity belongs to DHFR and 10% of the cellular dihydrofolate reductase activity belongs to pteridine reductase
-
-
-
additional information
?
-
-
in Cryptosporidium, DHFR and thymidylate synthase are present as a bifunctional enzyme, DHFR-TS
-
-
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
3-acetylpyridine adenine nucleotide
-
-
NADH
-
NADPH oxidized 5.1-times more rapidly than NADH
NADH
-
low activity
NADH
-
NADPH 16fold more active than NADH
NADH
-
chicken liver: at neutral pH specific for NADPH and 7,8-dihydrofolate, at acid pH: NADH + 7,8-dihydrofolate and folate + NADPH
NADP+
-
-
NADP+
-
-
NADPH
-
-
NADPH
-
cofactor-enzyme interaction study from x-ray structure, structural and topological comparison with dehydrogenases
NADPH
-
-
NADPH
-
interaction study
NADPH
Pigeon
-
-
NADPH
-
isozymes I and II
NADPH
-
NADPH oxidized 5.1-times more rapidly than NADH
NADPH
-
A-side specific
NADPH
-
specific
NADPH
-
NADPH 16fold more active than NADH
NADPH
-
wild-type and mutant enzymes
NADPH
B5U9U8
-
NADPH
Q2YY41
binding structure and comformation of wild-type and mutant enzyme
NADPH
-
binding strutcure and conformation, the adenine moiety adopts an off-plane tilt of nearly 90 and this orientation is stabilized by hydrogen bonds to functionally conserved Arg residues, hydrid transfer and structural role in catalytic mechanism, overview
NADPH
P13955
; the presence of NADPH greatly enhances binding of trimethoprim to DHFR
NADPH
J7GQW2
-
NADPH
AB986558
induces significant structural formation to the enzyme
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Cs+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild type enzyme activity above 0.1 mM
K+
-
activation of mutant type enzyme activity at 0.2 mM, decrease of wild type enzyme activity above 0.1 mM
K+
-
stimulation
K+
-
stimulation
K+
-
stimulation
K+
-
stimulation
KCl
-
maximal activity at 0.5 M
KCl
-
steady increase in activity from 0 to 1 M KCl
KCl
-
dihydrofolate reductase hvDHFR1 and hvDHFR2 unfold at KCl concentrations below 0.5 M. Above 1 M, the KCl dependence of the dihydrofolate reductase activities can be attributed to the effect of salt on substrate affinity
Li+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild type enzyme activity above 0.1 mM
Na+
-
activation of mutant type enzyme 0.2 mM, decrease of wild type enzyme activity above 0.1 mM
Na+
-
activates
Organic mercurials
-
animal enzyme: activated, bacterial enzyme: unaffected or inhibited
Organic mercurials
-
-
Organic mercurials
-
animal enzyme: activated, bacterial enzyme: unaffected or inhibited
Organic mercurials
-
no activation
Organic mercurials
-
no activation
Organic mercurials
-
cultured mammalian cells: activation
Ru+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild type enzyme activity above 0.1 mM
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(-)-epicatechin gallate
-
competitive to 7,8-dihydrofolate, formation of a slow dissociation ternary complex by the reaction of NADPH with the enzyme-inhibitor complex. Ionization state of E30 is critical for inhibitory activity
(-)-epigallocatechin gallate
-
competitive to 7,8-dihydrofolate, formation of a slow dissociation ternary complex by the reaction of NADPH with the enzyme-inhibitor complex. Ionization state of E30 is critical for inhibitory activity
(1E)-1-[4-[(3,5-dichloropyridin-4-yl)oxy]phenyl]ethanone thiosemicarbazone
-
-
(2,4-diaminopyrimidin-5-yl)methyl naphthalene-2-sulfonate
-
-
(2,4-diaminopyrimidin-5-yl)methyl naphthalene-2-sulfonate
P16184
-
(2,4-diaminopyrimidin-5-yl)methyl naphthalene-2-sulfonate
-
-
(2,5-dimethyl-1,4-phenylene)bis(methylene) bis(N-[amino(imino)methyl](imidothiocarbamate))
-
50% inhibition at 0.000075 mM
(2S)-2-((4-[(2-amino-6-ethyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)thio]benzoyl)amino)pentanedioic acid
-
50% inhibition at 0.00042 mM, additionally inhibitory on thymidylate synthase
(2S)-2-((4-[(2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)thio]benzoyl)amino)pentanedioic acid
-
50% inhibition at 0.0021 mM, additionally inhibitory on thymidylate synthase
(2S)-2-[(5-{methyl[(2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)formamido]pentanedioic acid
-
in low-folate medium, up to 300-fold increase of inhibitory activity
(4-(1-[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(methyl)amino]ethyl)phenyl)methanol
-
-
(E)-5-[2-(2-methoxyphenyl)prop-1-en-1-yl]furo[2,3-d]pyrimidine-2,4-diamine
-
DHFR binding structure, modelling, overview
(Z)-5-[2-(2-methoxyphenyl)prop-1-en-1-yl]furo[2,3-d]pyrimidine-2,4-diamine
-
DHFR binding structure, modelling, overview
1,1'-{6-[(4-nitrophenyl)amino]-1,3,5-triazine-2,4-diyl}bis(4-benzylpyrazinediium)
-
minimal inhibitory concentration: 0.003536 mM
1,1'-{6-[(4-nitrophenyl)amino]-1,3,5-triazine-2,4-diyl}bis(4-methylpyrazinediium)
-
minimal inhibitory concentration: 0.002418 mM
1,1'-{6-[(4-nitrophenyl)amino]-1,3,5-triazine-2,4-diyl}bis(4-phenylpyrazinediium)
-
minimal inhibitory concentration: 0.018 mM
1,3-phenylenebis(methylene) bis(N-[amino(imino)methyl](imidothiocarbamate))
-
50% inhibition at 0.000075 mM
1,4-bis-([N-(1-imino-1-guanidino-methyl)]sulfanylmethyl)-3,6-dimethyl-benzene
-
binding of the inhibitor has both a favorable entropy and enthalpy of binding. Positive binding cooperativity between inhibitor and the cofactor NADPH. Binding of inhibitor to DHFR is 285fold tighter in the presence of the NADPH cofactor than in its absence
1,4-phenylenebis(methylene) bis(N-[amino(imino)methyl](imidothiocarbamate))
-
-
1,6-bis-(4-fluoro-phenyl)-[1,3,5]triazine-2,4-diamine
-
IC50: 0.011 nM, 0.03 mM 7,8-dihydrofolate
1-(3-([(2,4-diaminopteridin-6-yl)methyl]amino)phenyl)ethanol
-
-
1-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
-
-
1-([N-(1-imino-guanidino-methyl)]sulfanylmethyl)-3-trifluoromethyl-benzene
-
binding of the inhibitor has both a favorable entropy and enthalpy of binding. Positive binding cooperativity between inhibitor and the cofactor NADPH. Binding of inhibitor to DHFR in the absence of NADPH is not observed
1-[3-(3,4-dichlorophenoxy)propyloxy]-5-isopropylbiguanide
-
i.e. PS-16
1-[3-(4-chlorophenoxy)propyloxy]-5-isopropylbiguanide
-
i.e. PS-33
2,2'-({6-[(4-nitrophenyl)amino]-1,3,5-triazine-2,4-diyl}diimino)diethanol
-
minimal inhibitory concentration: 0.149 mM
2,3-bis(hydrazino)quinoxaline
-
-
2,4,6-Trinitrobenzenesulfonic acid
-
-
2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine
-
-
2,4-diamino-5-((R)-3-(3,4,5-trimethoxyphenyl)but-1-ynyl)-6-methylpyrimidine
Q5CGA3
pH 7.0
2,4-diamino-5-((R)-3-(3,4,5-trimethoxyphenyl)but-1-ynyl)-6-methylpyrimidine
Q07422
pH 7.0
2,4-diamino-5-((S)-3-(3,4,5-trimethoxyphenyl)but-1-ynyl)-6-methylpyrimidine
Q5CGA3
pH 7.0
2,4-diamino-5-((S)-3-(3,4,5-trimethoxyphenyl)but-1-ynyl)-6-methylpyrimidine
Q07422
pH 7.0
2,4-diamino-5-(3-(2,5-dimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine
-
i.e. UCP120B, potent enzyme inhibitor of DHFR and bacterial growth, three-dimensional solution structure of the ternary complex with enzyme and NADPH cofactor determined by NMR from 20 mM TES, 50 mM KCl, 10 mM DTT, and 0.5 mM EDTA solution containing 2 mM of each ligand, comparison to the crystal structure of the ternary complex, overview. Analysis of structure and dynamics of the binary inhibitor-enzyme complex
2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)but-1-ynyl)-6-methylpyrimidine
Q5CGA3
pH 7.0
2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)but-1-ynyl)-6-methylpyrimidine
Q07422
pH 7.0
2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)but-1-ynyl)pyrimidine
Q5CGA3
pH 7.0
2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)but-1-ynyl)pyrimidine
Q07422
pH 7.0
2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-methylpyrimidine
Q5CGA3
pH 7.0
2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-methylpyrimidine
Q07422
pH 7.0
2,4-diamino-5-(3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-methylpyrimidine
Q5CGA3
pH 7.0
2,4-diamino-5-(3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-methylpyrimidine
Q07422
pH 7.0
2,4-diamino-5-(3-phenylprop-1-ynyl)-6-ethylpyrimidine
-
-
2,4-Diamino-5-adamantylpyrimidine
-
weak inhibition
2,4-Diamino-5-benzylpyrimidines
-
-
2,4-diamino-5-isopropyl-6-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
2,4-diamino-5-isopropyl-6-arylthio-7H-pyrrolo[2,3-d]pyrimidine
-
evaluation of cytotoxicity against 17 different tumor cell lines
2,4-diamino-5-isopropyl-6-arylthio-7H-pyrrolo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(1-naphthylthio)furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(2',3',5',6'-tetrafluoro-4'-trifluoromethylphenylsulfanyl)-furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(2',5'-dimethoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(2',6'-dichlorophenylsulfanyl)-furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(2',6'-dimethylphenylsulfanyl)-furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(2'-isopropyl-6'-methylphenylsulfanyl)-furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(2'-methoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(2-naphthylthio)furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(3',4'-dimethoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(3'-methoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-6-(4'-methoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
-
-
2,4-diamino-5-methyl-butylpyrido[2,3-d]pyrimidine
-
-
2,4-Diamino-5-phenyl-s-triazines
-
-
2,4-diamino-5-propyl-6-(1'-naphthylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
2,4-diamino-5-propyl-6-arylthio-7H-pyrrolo[2,3-d]pyrimidine
-
evaluation of cytotoxicity against 17 different tumor cell lines. GI values are below 100 nM
2,4-diamino-5-propyl-6-arylthio-7H-pyrrolo[2,3-d]pyrimidine
-
-
2,4-diamino-5-[(R)-3-(3-methoxy-5-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[(S)-3-(3-methoxy-5-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(2,3-dimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
-
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
-
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-npropylpyrimidine
-
-
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]pyrimidine
-
-
2,4-diamino-5-[3-(2-methoxy-5-phenylphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
-
-
2,4-diamino-5-[3-(2-phenyl-5-methoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
-
-
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)-3-methylbut-1-ynyl]-6-methylpyrimidine
Q6FPH0
-
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)-3-methylbut-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)pent-1-ynyl]-6-methylpyrimidine
Q6FPH0
-
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)pent-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-4-(2,6-diisopropylphenyl)phenyl)-but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-4-(2,6-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-4-(2-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-4-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(2,6-diisopropylphenyl)phenyl)-but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
Q6FPH0
-
2,4-diamino-5-[3-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(2-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
Q6FPH0
-
2,4-diamino-5-[3-(3-methoxy-5-(2-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(2-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(3,5-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
Q6FPH0
-
2,4-diamino-5-[3-(3-methoxy-5-(3,5-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(4-methoxyphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
Q6FPH0
-
2,4-diamino-5-[3-(3-methoxy-5-(4-methoxyphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(4-tertbutylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
Q6FPH0
-
2,4-diamino-5-[3-(3-methoxy-5-(4-tertbutylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(6-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
Q6FPH0
-
2,4-diamino-5-[3-(3-methoxy-5-(6-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-6-(2-hydroxydibenz[b,f]azepin-5-yl)methylpteridine
-
crystallization data
2,4-diamino-6-[N-(2,3,5-trichlorobenzyl)-N-ethylamino]quinazoline
-
-
2,4-diamino-6-[N-(2,5-dimethoxybenzyl)-N-cyclopropyl methylamino]quinazoline
-
-
2,4-diamino-6-[N-(2,5-dimethoxybenzyl)-N-ethylamino]quinazoline
-
-
2,4-diamino-6-[N-(2,5-dimethoxybenzyl)-N-propylamino]quinazoline
-
-
2,4-diamino-6-[N-(alpha-naphthyl)-N-ethylamino]quinazoline
-
-
2,4-diamino-6-[N-(benzyl)-N-ethylamino]quinazoline
-
-
2,4-diamino-6-[N-(beta-naphthyl)-N-cyclopropyl methylamino]-quinazoline
-
-
2,4-diamino-6-[N-(beta-naphthyl)-N-ethylamino]quinazoline
-
-
2,4-diamino-6-[N-(beta-naphthyl)-N-propylamino]quinazoline
-
-
2,4-diaminopyrimidine
-
-
2,4-diaminoquinazoline
-
derivatives
2,4-Dimamino-6-butylpyrido[2,3-d]pyrimidine
-
-
2,4-Pentanedione
-
-
2-(2-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-(naphthalen-1-yl)ethyl)amino)ethoxy)ethanol
-
-
2-(2-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)[1-(naphthalen-1-yl)ethyl]amino)ethoxy)ethanol
-
-
2-(3-(2-(hydroxyimino)-2-(pyridine-4-yl)-6,7-dimethylquinoxalin-2-yl)-1-(pyridine-4-yl)ethanone) oxime
-
i.e. 373265, a dual-site inhibitor, that targets both the substrate and cofactor binding site, docking modelling, overview
2-amino-4-oxo-6-methyl-5-phenylsulfanylthieno[2,3-d]pyrimidine
-
-
2-amino-5-(4-bromobenzyl)-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-amino-5-(4-chlorobenzyl)-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-amino-5-(4-methoxybenzyl)-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
-
2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-5-[(2-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
-
2-amino-5-[(3,4-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-5-[(3,4-dichlorophenyl)thio]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
-
2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-ethylthieno[2,3-d ]-pyrimidin-4(3H)-one
-
-
2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-5-[(3,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
-
2-amino-5-[(3-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
-
2-amino-5-[(4-bromophenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
-
-
2-amino-5-[(4-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-5-[(4-chlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-5-[(4-fluorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-6-ethyl-5-(2-naphthylthio)thieno[2,3-d ]pyrimidin-4(3H)-one
-
-
2-amino-6-ethyl-5-(phenylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-6-ethyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d ]pyrimidin-4(3H)-one
-
-
2-amino-6-ethyl-5-[(4-fluorophenyl)sulfanyl]thieno[2,3-d ]pyrimidin-4(3H)-one
-
-
2-amino-6-ethyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-6-methyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-6-methyl-5-(4-nitrobenzyl)-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-amino-6-methyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-6-methyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-amino-6-methyl-5-[4-(trifluoromethoxy)benzyl]-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-hydroxy-5-nitrobenzyl N-[amino(imino)methyl]imidothiocarbamate
-
50% inhibition at 0.0151 mM
2-methoxybenzyl N-[amino(imino)methyl]imidothiocarbamate
-
50% inhibition at 0.0033 mM
2-[(3-[3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenyl]prop-2-yn-1-yl)oxy]benzoic acid
-
ratio of IC50 values human/Trypanosoma enzyme 47
2-[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-yl]ethyl)amino]ethanol
-
-
2-[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(methyl)amino]-2-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethanol
-
-
2-[[(4-[[(2-amino-4-oxo-3,4-dihydropyrido[3,2-d]pyrimidin-6-yl)methyl]amino]phenyl)carbonyl]amino]hexanedioic acid
-
-
2-[[1-(3-chlorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl]carbonyl]-N-prop-2-en-1-ylhydrazinecarbothioamide
-
-
3,4-dichlorobenzyl N-[amino(imino)methyl]imidothiocarbamate
-
50% inhibition at 0.0037 mM
3,5-bis(trifluoromethyl)benzyl N-[amino(imino)methyl]imidothiocarbamate
-
50% inhibition at 0.0056 mM
3-((3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenoxy)methyl)benzoic acid
-
ratio of IC50 values human/Trypanosoma enzyme is 86
3-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-(naphthalen-1-yl)ethyl)amino)propanoic acid
-
-
3-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)[1-(naphthalen-1-yl)ethyl]amino)propanoic acid
-
-
3-(2,4-diamino-6-methylpyrimidin-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-ol
Q6FPH0
-
3-(2,4-diamino-6-methylpyrimidin-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-ol
-
-
3-(2,4-diamino-6-methylpyrimidin-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-ol
Q2YY41
-
3-(2,4-diamino-6-methylpyrimidin-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-ol
-
-
3-(2,4-diaminophenyl)-1-(3-(4-methylbenzyloxy)phenyl)prop-2-en-1-one
-
-
3-(2,4-diaminophenyl)-1-(3-(4-methylbenzyloxy)phenyl)prop-2-en-1-one
P16184
-
3-(2,4-diaminophenyl)-1-(3-(4-methylbenzyloxy)phenyl)prop-2-en-1-one
-
-
3-(2,4-diaminopyrimidin-5-yl)-1-(4-methoxyphenyl)-prop-2-en-1-one
-
-
3-(2,4-diaminopyrimidin-5-yl)-1-(4-methoxyphenyl)-prop-2-en-1-one
P16184
-
3-(2,4-diaminopyrimidin-5-yl)-1-(4-methoxyphenyl)-prop-2-en-1-one
-
-
3-(trifluoromethyl)benzyl N-[amino(imino)methyl]imidothiocarbamate
-
50% inhibition at 0.0043 mM
3-([(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]amino)-4-(2,5-dimethoxyethoxy)phenol
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 7.6
3-benzyl-6-[(3,4-dimethoxybenzyl)(methyl)amino]-2-(methylsulfanyl)quinazolin-4(3H)-one
-
50% inhibition at 0.001 mM
3-benzyl-6-[(4-methoxybenzyl)(methyl)amino]-2-(methylsulfanyl)quinazolin-4(3H)-one
-
50% inhibition at 0.0005 mM
3-heptyl-4-hydroxy-1H-naphthalen-2-one
-
IC50: 0.48 mM, 0.03 mM 7,8-dihydrofolate
3-methoxybenzyl N-[amino(imino)methyl]imidothiocarbamate
-
50% inhibition at 0.0038 mM
3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin
-
i.e. TMECG, synthesis of a trimethoxy derivative of epicatechin-3-gallate, which shows high antiproliferative and proapoptotic activity against melanoma. It is a prodrug that is selectively activated by the specific melanocyte enzyme tyrosinase. Upon activation, the compound generates a stable quinone methide product that strongly inhibits dihydrofolate reductase in an irreversible manner. The treatment of melanoma cells affects cellular folate transport and the gene expression of DHFR
3-[(3-(3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenyl)prop-2-yn-1-yl)oxy]benzoic acid
-
ratio of IC50 values human/Trypanosoma enzyme is 77
3-[(3-[3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenyl]prop-2-yn-1-yl)oxy]benzoic acid
-
ratio of IC50 values human/Trypanosoma enzyme is 77
3-[[(4-chlorophenyl)sulfonyl]methyl]-N'-hydroxybenzenecarboximidamide
-
-
4,5-dideoxy-5-(2,6-diamino-5-phenylpyrimidin-4-yl)-D-erythro-pentitol
-
selective inhibition, little effect on human or yeast enzyme
4,6-di(5,8-dihydro-1,7-naphthyridin-7(6H)-yl)-N-(4-nitrophenyl)-1,3,5-triazin-2-amine
-
minimal inhibitory concentration: 0.020 mM
4,6-di(morpholin-4-yl)-N-(4-nitrophenyl)-1,3,5-triazin-2-amine
-
minimal inhibitory concentration: 0.0258 mM
4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(phenylalkylphenyl)-s-triazines
-
bearing a terminal sulfonyl fluoride
4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)-N-(4-sulfamoylphenethyl)-benzamide
P00381
-
4-((2,4-diaminopteridin-6-yl)methylamino)-N-(4-sulfamoylphenethyl)benzamide
P00381
-
4-((2,4-diaminopteridin-6-yl)methylamino)benzenesulfonamide
P00381
-
4-((2,4-diaminopteridin-6-yl)methylamino)benzenesulfonic acid
P00381
-
4-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-(naphthalen-1-yl)ethyl)amino)butanoic acid
-
-
4-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)[1-(naphthalen-1-yl)ethyl]amino)butanoic acid
-
-
4-((5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl)ethynyl)benzoic acid
-
ratio of IC50 values human/Trypanosoma enzyme is 129
4-(2-(4-((2,4-diaminopteridin-6-yl)methylamino)benzamido)ethyl) benzenesulfonic acid
P00381
-
4-(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) butanoic acid
-
-
4-(benzyloxy)benzaldehyde thiosemicarbazone
-
-
4-(N-[(2,4-Diamino-6-pteridyl)methyl]-N-methylamino)benzoate
-
-
4-(trifluoromethyl)benzyl N-[amino(imino)methyl]imidothiocarbamate
-
50% inhibition at 0.013 mM
4-([(2,4-diaminopteridin-6-yl)methyl](methyl)amino)benzoic acid
-
-
4-([5-[(2,4-diaminopteridin-6-yl)methyl]-5H-dibenzo[b,f]azepin-2-yl]oxy)butane-1,1-diol
-
O-(3-carboxypropyl) inhibitor, crystallization data
4-benzyl-N-[3-benzyl-2-(methylsulfanyl)-4-oxo-3,4-dihydroquinazolin-6-yl]benzenesulfonamide
-
50% inhibition at 0.008 mM
4-bromo-N-[2-(methylthio)-4-oxo-3-phenyl-3,4-dihydroquinazolin-6-yl]benzenesulfonamide
-
50% inhibition at 0.002 mM
4-chloro-N-[4-(hydroxycarbamimidoyl)benzyl]benzamide
-
-
4-methylbenzyl N-[amino(imino)methyl]imidothiocarbamate
-
50% inhibition at 0.0126 mM
4-[(3,5-dichloropyridin-4-yl)oxy]-N'-hydroxybenzenecarboximidamide
-
-
4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]phenol
-
50% inhibition at 0.00165 mM
4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]phenol
-
50% inhibition at 0.0799 mM
4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]phenol
-
50% inhibition at 0.000034 mM
4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]phenol
-
50% inhibition at 0.000054 mM
4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]phenol
-
50% inhibition at 0.000078 mM
4-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]butanoic acid
Q81E04
50% inhibition of growth in culture at 0.00060 mM
4-[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy]benzaldehyde thiosemicarbazone
-
-
5,5'-dithiobis(2-nitrobenzoate)
-
-
5,5'-dithiobis(2-nitrobenzoate)
-
-
5,5'-dithiobis(2-nitrobenzoate)
-
-
5,6,7,8-tetrahydrofolate
-
non-competitive product inhibition
5-((10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-pyrimidine-2,4-diamine
-
-
5-((10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-pyrimidine-2,4-diamine
P16184
-
5-((10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-pyrimidine-2,4-diamine
-
-
5-((4-methoxyphenylamino)methyl)pyrimidine-2,4-diamine
-
-
5-((4-methoxyphenylamino)methyl)pyrimidine-2,4-diamine
P16184
-
5-((4-methoxyphenylamino)methyl)pyrimidine-2,4-diamine
-
-
5-((5H-dibenzo[b,f]azepin-5-yl)methyl)pyrimidine-2,4-diamine
-
-
5-((5H-dibenzo[b,f]azepin-5-yl)methyl)pyrimidine-2,4-diamine
P16184
-
5-((5H-dibenzo[b,f]azepin-5-yl)methyl)pyrimidine-2,4-diamine
-
-
5-((benzo[d]oxazol-2-ylthio)methyl)pyrimidine-2,4-diamine
-
-
5-((benzo[d]oxazol-2-ylthio)methyl)pyrimidine-2,4-diamine
P16184
-
5-((benzo[d]oxazol-2-ylthio)methyl)pyrimidine-2,4-diamine
-
-
5-((methyl(naphthalen-1-yl)amino)methyl)pyrimidine-2,4-diamine
-
-
5-((methyl(naphthalen-1-yl)amino)methyl)pyrimidine-2,4-diamine
P16184
-
5-((methyl(naphthalen-1-yl)amino)methyl)pyrimidine-2,4-diamine
-
-
5-((naphthalen-1-ylamino)methyl)pyrimidine-2,4-diamine
-
-
5-((naphthalen-1-ylamino)methyl)pyrimidine-2,4-diamine
P16184
-
5-((naphthalen-1-ylamino)methyl)pyrimidine-2,4-diamine
-
-
5-(3,4,5-trimethoxy-benzyl)-pyrimidine-2,4-diamine
-
IC50: 18 nM, 0.03 mM 7,8-dihydrofolate
5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(3-chlorophenyl)-6-(3-phenylpropyl)pyrimidine-2,4-diamine
-
-
5-(3-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(4-bromophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-(4-methoxyphenyl)pyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-isobutylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-isopropylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-phenylpyrimidine-2,4-diamine
-
very high Ki-value
5-(4-chlorophenyl)-6-phenylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-propylpyrimidine-2,4-diamine
-
-
5-(5-[[(2,4-diamino-6-quinazolinyl)methyl](propyl)amino]-2-methoxyphenoxy) pentanoate
-
-
5-(methoxymethyl)-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-ethyl-6-([[2-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-ethyl-6-([[2-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-ethyl-6-[[(2-methoxy-5-methylphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-ethyl-6-[[(2-methoxy-5-methylphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methoxy-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(5,6,7,8-tetrahydronaphthalen-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-1-ylsulfanyl)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-2-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-2-ylsulfanyl)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(pyren-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(quinolin-3-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(quinolin-5-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(quinolin-6-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3,4,5-trimethoxyphenyl)sulfanyl]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3,4,5-trimethoxyphenyl)sulfanyl]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3-methylphenyl)sulfanyl]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3-methylphenyl)sulfanyl]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyltetrahydrofolate
-
-
5-nitro-6-methylamino-isocytosine
-
inhibitor of dihydropteroate synthase, also acts on dihydrofolate reductase
-
5-phenyl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine
-
selective inhibition of Mycobacterium tuberculosis enzyme, little effect on human or yeast enzyme
5-[(R/S)-2-(2'-methoxyphenyl)-3-methylbutyl]furo[2,3-d]-pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-(2'-methoxyphenyl)-3-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-(2'-methoxyphenyl)-4-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-(2'-methoxyphenyl)hexyl]furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-(2'-methoxyphenyl)pentyl]furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(R/S)-2-cyclopropyl-2-(2'-methoxyphenyl)ethyl]furo-[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)-3-methylbut-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)-3-methylpent-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)-4-methylpent-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)hex-1-en-1-yl]furo[2,3-d]-pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-(2'-methoxyphenyl)pent-1-en-1-yl]furo[2,3-d]-pyrimidine-2,4-diamine
-
-
5-[(Z/E)-2-cyclopropyl-2-(2'-methoxyphenyl)vinyl]furo-[2,3-d]pyrimidine-2,4-diamine
-
-
5-[3-(2,5-dimethoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
-
-
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
-
-
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-propylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
Q2YY41
-
5-[3-(2-methoxy-2',6'-dimethylbiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(2-methoxy-2'-methylbiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(2-methoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(2-methoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-(3-methoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(5-methoxy-2'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q6FPH0
-
5-[3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-(biphenyl-3-yl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
-
-
5-[3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q6FPH0
-
5-[3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
Q2YY41
-
5-[3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]pentanoic acid
Q81E04
50% inhibition of growth in culture at 0.00167 mM
5-[3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]but-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
-
-
5-[3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
-
-
5-[3-[3-methoxy-5-(morpholin-4-yl)phenyl]but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
5-[3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
-
6,7-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine
-
IC50: 790 nM, 0.03 mM 7,8-dihydrofolate
6-((10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-1,3,5-triazine-2,4-diamine
-
-
6-((10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-1,3,5-triazine-2,4-diamine
P16184
-
6-((10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-1,3,5-triazine-2,4-diamine
-
-
6-((10H-phenothiazin-10-yl)methyl)-1,3,5-triazine-2,4-diamine
-
-
6-((10H-phenothiazin-10-yl)methyl)-1,3,5-triazine-2,4-diamine
P16184
-
6-((10H-phenothiazin-10-yl)methyl)-1,3,5-triazine-2,4-diamine
-
-
6-((2-chloro-10H-phenothiazin-10-yl)methyl)-1,3,5-triazine-2,4-diamine
-
-
6-((2-chloro-10H-phenothiazin-10-yl)methyl)-1,3,5-triazine-2,4-diamine
P16184
-
6-((2-chloro-10H-phenothiazin-10-yl)methyl)-1,3,5-triazine-2,4-diamine
-
-
6-((5-methoxy-2-methylphenylamino)methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-(([4-chlorotricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]amino)methyl)pteridine-2,4-diamine
-
-
6-(2-(5H-dibenzo[b,f]azepin-5-yl)ethoxy)pyrimidine-2,4-diamine
-
-
6-(2-(5H-dibenzo[b,f]azepin-5-yl)ethoxy)pyrimidine-2,4-diamine
P16184
-
6-(2-(5H-dibenzo[b,f]azepin-5-yl)ethoxy)pyrimidine-2,4-diamine
-
-
6-(2-[4-(benzyloxy)phenyl]ethyl)quinazoline-2,4-diamine
-
50% inhibition at 0.00185 mM
6-(2-[4-(benzyloxy)phenyl]ethyl)quinazoline-2,4-diamine
-
50% inhibition at 0.0138 mM
6-(2-[4-(benzyloxy)phenyl]ethyl)quinazoline-2,4-diamine
-
50% inhibition at 0.00012 mM
6-(2-[4-(benzyloxy)phenyl]ethyl)quinazoline-2,4-diamine
-
50% inhibition at 0.0001 mM
6-(2-[4-(benzyloxy)phenyl]ethyl)quinazoline-2,4-diamine
-
50% inhibition at 0.000059 mM
6-(3,4,5-trimethoxybenzyloxy)pyrimidine-2,4-diamine
-
-
6-(3,4,5-trimethoxybenzyloxy)pyrimidine-2,4-diamine
P16184
-
6-(3,4,5-trimethoxybenzyloxy)pyrimidine-2,4-diamine
-
-
6-(4-trifluoromethyl-phenoxy)-quinazoline-2,4-diamine
-
IC50: 660 nM, 0.03 mM 7,8-dihydrofolate
6-([(1E)-(4-methoxyphenyl)methylene]amino)-2-(methylthio)-3-phenylquinazolin-4(3H)-one
-
50% inhibition at 0.002 mM
6-([(2,5-dipropoxyphenyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 65
6-([(2-bromo-3,4,5-trimethoxyphenyl)amino]methyl)quinazoline-2,4-diamine
Q81E04
50% inhibition of growth in culture at 0.0011 mM
6-([(2-butoxy-5-ethoxyoxyphenyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 2.8
6-([(2-butoxy-5-propoxyphenyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 19
6-([(2-ethoxy-5-butoxyphenyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 4.1
6-([(3-nitrophenyl)amino]methyl)pteridine-2,4-diamine
-
-
6-([(4-aminophenyl)amino]methyl)pteridine-2,4-diamine
-
-
6-([(4-ethoxyphenyl)amino]methyl)pteridine-2,4-diamine
-
-
6-([5-quinolylamino]-methyl)-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine
-
enzyme-bound crystal structure analysis for inhibitor screening and docking studies, PDB ID 1KMS
6-([butyl(phenyl)amino]methyl)pteridine-2,4-diamine
-
-
6-([ethyl(phenyl)amino]methyl)pteridine-2,4-diamine
-
-
6-([methyl(3-nitrophenyl)amino]methyl)pteridine-2,4-diamine
-
-
6-([methyl(phenyl)amino]methyl)pteridine-2,4-diamine
-
-
6-([phenyl(prop-2-en-1-yl)amino]methyl)pteridine-2,4-diamine
-
-
6-([phenyl(propan-2-yl)amino]methyl)pteridine-2,4-diamine
-
-
6-([phenyl(propyl)amino]methyl)pteridine-2,4-diamine
-
-
6-([tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-ylamino]methyl)pteridine-2,4-diamine
-
-
6-([tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-ylamino]methyl)pteridine-2,4-diamine
-
-
6-([[2-(difluoromethoxy)-5-methylphenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-(difluoromethoxy)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-bromo-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-bromo-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-fluoro-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-fluoro-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-methoxy-5-(trifluoromethyl)phenyl](methyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[3-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[3-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[4-(difluoromethoxy)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[4-(fluoromethoxy)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-amino-3-pentadecylphenyl beta-D-glucoside
-
i.e. 1357, a dual-site inhibitor, that targets both the substrate and cofactor binding site
6-ethyl-5-(4-methoxyphenyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-phenylpyrimidine-2,4-diamine
O02604
analogue of pyrimethamine lacking the 4-Cl group, effectively inhibits both wild-type and pyrimethamine-resistant mutant S58R/S117N
6-ethyl-5-[3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-ethyl-5-[3-(4-methoxybiphenyl-3-yl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-ethyl-5-[3-[3-(isoquinolin-5-yl)-5-methoxyphenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-ethyl-5-[3-[3-(isoquinolin-5-yl)-5-methoxyphenyl]prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-ethyl-5-[3-[3-methoxy-5-(morpholin-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-ethyl-5-[3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
Q6FPH0
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
Q2YY41
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)pent-1-yn-1-yl]pyrimidine-2,4-diamine
Q2YY41
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)pent-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
Q6FPH0
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
Q2YY41
-
6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
-
-
6-p-tolyloxy-quinazoline-2,4-diamine
-
IC50: 190 nM, 0.03 mM 7,8-dihydrofolate
6-p-tolylsulfanyl-quinazoline-2,4-diamine
-
IC50: 310 nM, 0.03 mM 7,8-dihydrofolate
6-[(3,4-dimethoxyanilino)methyl]-2,4-quinazolinediamine
-
-
6-[(4-methoxybenzyl)(methyl)amino]-2-(methylsulfanyl)-3-phenylquinazolin-4(3H)-one
-
50% inhibition at 0.001 mM
6-[(9H-fluoren-2-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(9H-fluoren-9-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(anthracen-9-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(fluoranthen-3-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(isoquinolin-5-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(phenylamino)methyl]pteridine-2,4-diamine
-
-
6-[(tricyclo[4.3.0.07,9]nona-1,3,5-trien-3-ylamino)methyl]pteridine-2,4-diamine
-
-
6-[2-(2,5-dimethoxyphenyl)ethyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[2-(2,5-dimethoxyphenyl)ethyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[2-(3,5-dimethoxyphenyl)ethyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[2-(3,5-dimethoxyphenyl)ethyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[2-(4-butoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00204 mM
6-[2-(4-butoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.0017 mM
6-[2-(4-butoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.000044 mM
6-[2-(4-butoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00023mM
6-[2-(4-butoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.000042 mM
6-[2-(4-ethoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00234 mM
6-[2-(4-ethoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.002 mM
6-[2-(4-ethoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00018 mM
6-[2-(4-ethoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.000081 mM
6-[2-(4-ethoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.000041 mM
6-[2-(4-hexoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00347 mM
6-[2-(4-hexoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.0021 mM
6-[2-(4-hexoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.000177 mM
6-[2-(4-hexoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.000095 mM
6-[2-(4-hexoxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00011 mM
6-[2-(4-octyloxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.01289 mM
6-[2-(4-octyloxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.002 mM
6-[2-(4-octyloxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.000123 mM
6-[2-(4-octyloxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00035 mM
6-[2-(4-octyloxyphenyl)ethyl]quinazoline-2,4-diamine
-
50% inhibition at 0.00022 mM
6-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]hexanoic acid
Q81E04
50% inhibition of growth in culture at 0.00051 mM
6-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenyl]hex-5-ynoic acid
Q81E04
50% inhibition of growth in culture at 0.00190 mM
6-[[(2,5-dibromophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dibromophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dibutoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dichlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dichlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-diethoxyphenyl)(methyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-diethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-diethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-diethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-difluorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-difluorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-ethylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-ethylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
; identified from docking studies
6-[[(2,5-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2,5-dipropoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-4,6-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-4,6-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-4-fluoro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-4-fluoro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-fluoro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-fluoro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-methoxy-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-methoxy-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dichlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dichlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,4-dimethoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,5-dimethoxyphenyl)(methyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,5-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3,5-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-bromo-4-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-bromo-4-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chloro-4-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chlorophenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chlorophenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-ethoxy-5-methoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-fluoro-4-methoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-fluoro-4-methoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-methoxy-5-propoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-methoxybiphenyl-4-yl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-methoxybiphenyl-4-yl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-methoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-methoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-bromo-2,6-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-bromo-2,6-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-bromo-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-bromo-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-bromo-3-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-butoxy-3-methoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chloro-2-methoxy-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chloro-2-methoxy-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chloronaphthalen-1-yl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]-5-methoxypyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(5-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(5-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(5-fluoro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(5-fluoro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(5-methoxy-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
7,8-dihydrofolate
-
substrate inhibition at concentration above 0.008 mM for native enzyme and at concentration above 0.001 mM for the recombinant enzyme
7-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine
-
IC50: 0.011 nM, 0.03 mM 7,8-dihydrofolate
7-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenyl]hept-6-ynoic acid
Q81E04
50% inhibition of growth in culture at 0.000027 mM
7-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]hept-6-ynoic acid
-
ratio of IC50 values human/Trypanosoma enzyme is 49
aminopterin
-
-
aminopterin
-
-
aminopterin
-
-
aminopterin
-
-
aminopterin
-
-
aminopterin
-
-
aminopterin
-
-
aminopterin
-
-
aminopterin
-
-
AR-101
P0A017
i.e. 5-[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromene-5-ylmethyl]pyrimidine-2,4-diamine, binding structure from crystal structure, the cyclopropyl-dimethoxychromene moiety interacts with the conserved residues Leu28, Val31, Ile50 and Leu54 forming a hydrophobic pocket in the enzyme
Ar-102
P0A017
i.e. 5-[(2S)-2-cyclopropyl-7,8-dimethoxy-2H-chromene-5-ylmethyl]pyrimidine-2,4-diamine, binding structure from crystal structure, the cyclopropyl-dimethoxychromene moiety interacts with the conserved residues Leu28, Val31, Ile50 and Leu54 forming a hydrophobic pocket in the enzyme
BAL0030543
-
a dihydrophthalazine inhibitor with antibacterial activity, overview
BAL0030544
-
a dihydrophthalazine inhibitor with antibacterial activity, overview
BAL0030545
-
a dihydrophthalazine inhibitor with antibacterial activity, overview
benzaldehyde semicarbazone
-
-
Bromoacetate
-
-
Ca2+
-
recombinant enzyme, above 20 mM
Chaotrophes
-
e.g. guanidine-HCl; formamide; urea
-
Chaotrophes
-
e.g. guanidine-HCl
-
chlorocycloguanil
-
-
Chloroquine
-
mean 50% inhibitory concentration 74.94 ng/ml in dihydrofolated reductase wild-type from five isolates of Plasmodium malariae collected from five countries in Asia and Africa
Chloroquine
-
-
citrate
-
in acid pH range: inhibitor of reduction of 7,8-dihydrofolate but not folate
clociguanil
Q00NX3
-
Cs+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild-type enzyme activity above 0.1 mM
cycloguanil
-
wild-type and several Ser108 mutant enzymes
cycloguanil
-
wild-type and mutant
cycloguanil
Q00NX3
-
cycloguanil
-
an antifolate enzyme inhibitor used in treatment of malaria
cycloguanil
-
and prodrug proguanil
cycloguanil
-
-
Dansyl chloride
-
-
deoxytubulosine
-
beta-carboline-benzoquinolizidine plant alkaloid derived from Alangium lamarckii, linear, non-competitive
deoxytubulosine
-
-
Diaminobutane
-
12 mM
Diaminopentane
-
12 mM
Dichloromethotrexate
-
-
diethyldicarbonate
-
-
Epicatechin gallate
-
-
epicatechin-3-O-gallate
-
-
epigallocatechin gallate
-
bisubstrate inhibitor, binds both on substrate and cofactor site of dihydrofolate reductase. Detailed study on kinetics
epigallocatechin gallate
-
-
epigallocatechin-3-gallate
-
IC50 value around 0.1 mM
epigallocatechin-3-O-gallate
-
-
ethyl 4-(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) butanoate
-
-
ethyl 4-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]butanoate
Q81E04
50% inhibition of growth in culture at 0.00088 mM
ethyl 5-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]pentanoate
Q81E04
50% inhibition of growth in culture at 0.00035 mM
ethyl 6-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]hexanoate
Q81E04
50% inhibition of growth in culture at 0.00185 mM
ethylenediamine
-
12 mM
folate
-
NADPH stabilizes against intracellular inactivation via folate
folate
-
-
folate
-
-
folate
-
substrate inhibition, IC50 value around 0.02 mM
folic acid
-
use in yeast protein fragment complementation assay system to prevent endogenous dihydrofolate reductase activity
grape seed extract
-
grape seed extract inhibits the dihydrofolate reductase activity and growth of Staphylococcus aureus. The grape seed extract-induced growth inhibition is reversed by adding, tetrahydrofolate, 5,10-methylenetetrahydrofolate or methionine to the medium
-
Guanidine-HCl
-
above 0.25 M
Guanidine-HCl
-
recombinant enzyme, 0.5 M
iclaprim
P0A017
binding structure from crystal structure
iodoacetamide
-
-
iodoacetamide
-
under high salt condition
Isoniazid
P9WNX1
acyclic 4R isonicotinoyl-NADP adduct binds to enzyme
K+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild-type enzyme activity above 0.1 mM
KCl
-
recombinant enzyme, concentration above 0.1 M
L-erythro-biopterin
-
-
L-tryptophyl-L-tyrosyl-L-tyrosine
-
development of a tri-peptide inhibitor using a structure-based drug design approach, docking studies and molecular dynamics, overview
Li+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild-type enzyme activity above 0.1 mM
Mercuric chloride
-
-
methasquin
-
-
methopterin
-
-
methotrexate
-
-
methotrexate
-
dihydrofolate antagonist drug
methotrexate
-
also ornithine, lysine and dansyl analogs of methotrexate
methotrexate
-
dihydrofolate antagonist drug
methotrexate
-
dihydrofolate antagonist drug
methotrexate
-
structure
methotrexate
-
-
methotrexate
-
-
methotrexate
-
-
methotrexate
-
-
methotrexate
-
i.e. N10-methylpteroylglutamic acid
methotrexate
-
-
methotrexate
-
-
methotrexate
-
-
methotrexate
-
-
methotrexate
-
-
methotrexate
-
-
methotrexate
-
-
methotrexate
-
-
methotrexate
-
dihydrofolate antagonist drug
methotrexate
-
biphasic inhibition at pH 7.0, competitive against 7,8-dihydrofolate; dihydrofolate antagonist drug
methotrexate
-
wild-type
methotrexate
-
cell line HeLa BU-25
methotrexate
-
-
methotrexate
-
recombinant enzyme
methotrexate
-
-
methotrexate
-
competitive
methotrexate
-
-
methotrexate
-
recombinant enzyme
methotrexate
-
-
methotrexate
-
wild-type and mutant
methotrexate
-
complete inhibition at 0.0001 mM, slow tight binding inhibitor
methotrexate
-
-
methotrexate
-
wild-type enzyme, slow binding
methotrexate
-
recombinant enzyme
methotrexate
-
IC50: 1.2 nM
methotrexate
-
IC50: 8.3 nM
methotrexate
Q70YQ6
IC50: 14.5 nM
methotrexate
P17719
wild-type, 50% inhibition at 1.06 nM, mutant Q134K, 50% inhibition at 16.7 nM, mutant L30Q, 50% inhibition at 785 nM
methotrexate
-
; wild-type, 50% inhibition at 0.00031 mM
methotrexate
-
50% inhibition at 0.000022 mM
methotrexate
-
50% inhibition at 0.000003 mM
methotrexate
-
50% inhibition at 0.000000436 mM, recombinant rat-derived enzyme, 50% inhibition at 0.0000029 mM, recombinant human-derived enzyme
methotrexate
-
60 nM, complete inhibition
methotrexate
-
slow-binding inhibition due to the generation of a long-lived, slowly dissociating enzyme-NADPH-inhibitor complex. One-step inhibition mechanism
methotrexate
-
in low-folate medium, up to 300-fold increase of inhibitory activity
methotrexate
B5U9U8
-
methotrexate
-
binding structure, overview
methotrexate
-
-
methotrexate
-
-
methotrexate
-
enzyme-bound crystal structure analysis for inhibitor screening and docking studies, PDB ID 1RA3
methyl 4-(2,6-diamino-5-phenylpyrimidin-4-yl)butanoate
-
-
methyl 4-([(2,4-diaminopteridin-6-yl)methyl](methyl)amino)benzoate
-
-
methyl 4-[(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) methyl]benzene carboxylate
-
-
methyl 4-[2,6-diamino-5-(3-chlorophenyl)pyrimidin-4-yl]butanoate
-
-
methyl 5-(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) pentanoate
-
-
methyl 5-[(1E)-N-carbamoylethanehydrazonoyl]-2,3'-bithiophene-5'-carboxylate
-
-
methylene blue
-
-
methylmercuric hydroxide
-
-
N-(4-chloro-2-cyanophenyl)imidodicarbonimidic diamide
-
IC50: 320 nM, 0.03 mM 7,8-dihydrofolate
N-(4-nitrophenyl)-4,6-di(piperidin-1-yl)-1,3,5-triazin-2-amine
-
minimal inhibitory concentration: 0.130 mM
N-(4-nitrophenyl)-4,6-di(pyrrolidin-1-yl)-1,3,5-triazin-2-amine
-
minimal inhibitory concentration: 0.140 mM
N-(4-[(2-amino-6-ethyl-4-oxo-3,4-dihydrothieno[2,3-d ]pyrimidin-5-yl)thio]benzoyl)-L-glutamic acid
-
-
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl]benzoyl)-L-glutamic acid
-
dual inhibitor of both dihydrofolate reductase and thymidylate synthase. Inhibitory to Toxoplasma gondii dihydrofolate reductase, little inhibition of Escherichia coli enzyme
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl]benzoyl)-L-glutamic acid
-
inhibitory to human dihydrofolate reductase, little inhibition of Escherichia coli enzyme
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d ]pyrimidin-5-yl)thio]benzoyl)-L-glutamic acid
-
-
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl)-L-glutamic acid
-
binding mode, overview
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamyl-gamma-glutamyl-gamma-glutamylglutamic acid
-
-
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamylglutamic acid
-
-
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid
-
-
N-(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)-N-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethyl)-beta-alanine
-
-
N-(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)-N-[1-(2-ethoxynaphthalen-1-yl)ethyl]-b-alanine
-
-
N-([5-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2,3-dihydrothiophen-2-yl]carbonyl)-4-methylideneglutamic acid
-
-
N-bromosuccinimide
-
-
N-ethylmaleimide
-
-
N-ethylmaleimide
-
-
N-ethylmaleimide
-
-
N-[(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]phenyl)carbonyl]glutamic acid
Q81E04
50% inhibition of growth in culture at 0.000024 mM
N-[2-(methylsulfanyl)-4-oxo-3-phenyl-3,4-dihydroquinazolin-6-yl]biphenyl-4-sulfonamide
-
50% inhibition at 0.005 mM
N-[2-(methylthio)-4-oxo-3-phenyl-3,4-dihydroquinazolin-6-yl]benzenesulfonamide
-
50% inhibition at 0.002 mM
N-[3-benzyl-2-(methylsulfanyl)-4-oxo-3,4-dihydroquinazolin-6-yl]-4-methylbenzenesulfonamide
-
50% inhibition at 0.007 mM
N-[3-benzyl-2-(methylthio)-4-oxo-3,4-dihydroquinazolin-6-yl]-4-bromobenzenesulfonamide
-
50% inhibition at 0.005 mM
N-[4-[(2,4-diamino-5-methyl-furo[2,3-d]pyrimidin-6-yl)-thio]-benzoyl]-L-glutamic acid
-
-
N-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2-fluorobenzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2-amino-4-methylquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N10-formylaminopterin
-
competitive against 7,8-dihydrofolate and noncompetitive against NADPH
N10-formylaminopterin
-
-
N10-formylaminopterin
-
-
N10-formylaminopterin
-
-
N10-formylaminopterin
-
-
N2,N2,N4,N4-tetraethyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.027 mM
N2,N4-bis(3-fluorophenyl)-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.022968 mM
N2,N4-bis[2-(morpholin-4-yl)ethyl]-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0042 mM
N2,N4-bis[3-(1H-imidazol-1-yl)propyl]-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0021 mM
N2,N4-bis[3-(morpholin-4-yl)propyl]-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0039 mM
N2,N4-di-tert-butyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.139 mM
N2,N4-dibenzyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.023393 mM
N2,N4-dibutyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0055 mM
N2,N4-dicycloheptyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0041 mM
N2,N4-dicyclohexyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0024 mM
N2-(4-nitrophenyl)-N4,N6-dioctyl-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.021 mM
N6-(2,5-dimethoxybenzyl)-N6-methylpyrido[2,3-d]pyrimidine-2,4,6-triamine
-
-
N6-(2,5-dimethoxybenzyl)-N6-methylquinazoline-2,4,6-triamine
-
-
N6-(2,5-dimethoxybenzyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine
-
-
N6-(2,5-dimethoxybenzyl)quinazoline-2,4,6-triamine
-
-
N7-(1-(naphthalen-1-yl)ethyl)-N7-propylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(2-aminoethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(2-aminoethyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(2-ethoxyethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(2-ethoxyethyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(2-propoxyethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(2-propoxyethyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(3-ethoxypropyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(3-ethoxypropyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(4-aminobutyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(4-aminobutyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(5-aminopentyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(5-aminopentyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(cyclopropylmethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(cyclopropylmethyl)-N7-[1-(4-methylnaphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(cyclopropylmethyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(prop-2-en-1-yl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-(prop-2-en-1-yl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-benzyl-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-benzyl-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-benzyl-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-butyl-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-butyl-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-cyclopropyl-N7-(1-(naphthalen-2-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-cyclopropyl-N7-[1-(naphthalen-2-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-ethyl-N7-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-ethyl-N7-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-yl]ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-ethyl-N7-(4-methylbenzyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-ethyl-N7-[1-(4-methylnaphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-methyl-N7-(1-phenylethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-methyl-N7-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-methyl-N7-[1-(4-methylnaphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-methyl-N7-[1-(quinolin-4-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-methyl-N7-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-ylmethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-pentyl-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-pentyl-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[1-(1-benzothiophen-3-yl)ethyl]-N7-(cyclopropylmethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[1-(1-benzothiophen-3-yl)ethyl]-N7-ethylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[1-(1-benzothiophen-3-yl)ethyl]-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[1-(2-ethoxynaphthalen-1-yl)ethyl]-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[1-(2-ethylnaphthalen-1-yl)ethyl]-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[1-(4-chloronaphthalen-1-yl)ethyl]-N7-(cyclopropylmethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[1-(naphthalen-1-yl)ethyl]-N7-propylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[2-(4-fluorophenyl)ethyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[2-(4-fluorophenyl)ethyl]-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[2-(cyclohex-2-en-1-yl)ethyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[2-(cyclohex-2-en-1-yl)ethyl]-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[3-(2-methyl-4H-imidazol-4-yl)propyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[3-(2-methyl-4H-imidazol-4-yl)propyl]-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[3-(2-methylpropoxy)propyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
N7-[3-(2-methylpropoxy)propyl]-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
-
Na+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild-type enzyme activity above 0.1 mM
NaCl
-
up to 20% increase in activity up to 0.2 M, activity declines above and falls to zero at 0.8 M
NADP+
-
-
NADP+
-
-
NADP+
-
non-competitive product inhibition
NCI0086195
-
docking analysis, overview
NCI0109835
-
docking analysis, overview
NCI0156252
-
docking analysis, overview
NCI0164641
-
docking analysis, overview
NCI0211175
-
docking analysis, overview
NCI0289533
-
docking analysis, overview
NCI0289541
-
docking analysis, overview
NCI0309401
-
docking analysis, overview
NCI0369769
-
docking analysis, overview
NCI0696662
-
docking analysis, overview
NH4+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild-type enzyme activity above 0.1 mM
OAAG324
-
i.e. 6-([(2,5-dichlorophenyl)amino]methyl)pyrido[2,3-d]pyrimidine-2,4-diamine, 50% inhibition at 0.000262 mM, recombinant rat-derived enzyme, 50% inhibition at 0.0075 mM, recombinant human-derived enzyme
OAAG373
-
i.e. 6-([(3,4,5-trichlorophenyl)amino]methyl)pyrido[2,3-d]pyrimidine-2,4-diamine, 50% inhibition at 0.000139 mM, recombinant rat-derived enzyme, 50% inhibition at 0.00094 mM, recombinant human-derived enzyme
Organic mercurials
-
animal enzyme: activated, bacterial enzyme: unaffected or inhibited
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-hydroxymercuribenzoate
-
-
p-hydroxymercuribenzoate
-
-
p-hydroxymercuribenzoate
-
-
p-hydroxymercuribenzoate
-
-
p-mercuribenzoate
-
mutant enzyme: no effect, wild type: inhibition
pegularinine
-
plant alkaloid
pemetrexed
-
i.e. LY231514, 50% inhibition at 0.0066 mM
peroxynitrite
-
0.1 mM, 50% inhibition of cysteine-free mutant C85S/C152E, no inhibition of wild-type
Phenylglyoxal
-
total inactivation
phenylmercuric acetate
-
mutant enzyme: no effect, wild type enzyme: inhibition
piritrexim
-
recombinant enzyme
piritrexim
-
recombinant enzyme
piritrexim
-
-
pralatrexate
-
-
PT682
-
O-(3-carboxypropyl) inhibitor, crystallization data
Pteroate
-
-
PY957
-
i.e. 5-(3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenoxy)pentanoic acid, 50% inhibition at 0.00009833 mM, recombinant rat-derived enzyme
pyrimethamine
-
i.e. 2,4-diamino-5-p-chlorophenyl-6-ethylpyridine
pyrimethamine
-
-
pyrimethamine
-
-
pyrimethamine
-
-
pyrimethamine
-
-
pyrimethamine
-
-
pyrimethamine
-
-
pyrimethamine
-
-
pyrimethamine
-
poor inhibitor
pyrimethamine
-
-
pyrimethamine
-
wild-type and several mutants of Ser108
pyrimethamine
-
recombinant enzyme
pyrimethamine
-
-
pyrimethamine
-
wild-type and mutant
pyrimethamine
-
anti-malarial DHFR inhibitor
pyrimethamine
-
study on Plasmodium falciparum isolates from 118 children in Cote d'Ivoire. 39.5% are highly resistant to pyrimethamine, with IC50 values above 2000 nM. 39% of the isolates have mutant dihydrofolate reductase and 94% mutant dihydropteroate synthetase genes, and mutant dihydrofolate reducatase is assovciated with resistance to pyrimethamine in vivo and in vitro
pyrimethamine
-
50% inhibition at 0.0024 mM, recombinant rat-derived enzyme, 50% inhibition at 0.0021 mM, recombinant human-derived enzyme
pyrimethamine
-
mean 50% inhibitory concentration 2.24 ng/ml in dihydrofolated reductase wild-type from five isolates of Plasmodium malariae collected from five countries in Asia and Africa
pyrimethamine
-
CoMFA and quantum chemical calculations studies on pyrimethamine derivatives active against quadruple mutant N5I/C59R/S108N/I164L. Residue N108 is the cause of pyrimethamine resistance with the highest repusive interaction energy
pyrimethamine
-
-
pyrimethamine
-
-
pyrimethamine
-
no increase in inhibitory activity in low-folate medium
pyrimethamine
B5U9U8
-
pyrimethamine
-
an antifolate enzyme inhibitor used in treatment of malaria
pyrimethamine
-
-
quinone methide
-
essentially irreversible inhibition
RAB1
-
i.e. (S,E)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(1-propylphthalazin-2(1H)-yl)prop-2-en-1-one or BAL17662, a dihydrophthalazine-based trimethoprim derivative, synthesis, overview. Binding of RAB1 causes a conformational change of the side chain of Arg58 and Met37 to accommodate the dihydrophthalazine moiety. The dihydrophthalazine group provides a large hydrophobic anchor that embeds within the DHFR active site and accounts for its selective inhibitory activity against Bacillus anthracis, binding structure, overview
-
Rose bengal
-
-
Ru+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild-type enzyme activity above 0.1 mM
-
Sodium dodecyl sulfate
-
recombinant enzyme, 0.1 M
Sodium tetrathionate
-
thiol-blocking reagent
spermidine
-
12 mM
spermine
-
12 mM
sulfanilamide
-
use in yeast protein fragment complementation assay system to prevent endogenous dihydrofolate reductase activity
tetrahydrofolate
-
product inhibition
Triampterene
-
-
Triazinate
-
-
trimepthoprim
-
-
trimethoprim
-
-
trimethoprim
-
folate antagonist drug
trimethoprim
-
-
trimethoprim
-
folate antagonist drug
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
-
folate antagonist drug
trimethoprim
-
poor inhibitor
trimethoprim
-
hDHFR-1 is much more resistant than hDHFR-2
trimethoprim
-
-
trimethoprim
-
recombinant enzyme
trimethoprim
-
-
trimethoprim
-
wild-type and mutant
trimethoprim
-
-
trimethoprim
-
IC50: 0.0825 mM
trimethoprim
-
IC50: 0.0165 mM
trimethoprim
Q70YQ6
IC50: 0.0048 mM
trimethoprim
-
50% inhibition at 0.254 mM
trimethoprim
-
; wild-type, 50% inhibition at 0.0089 mM
trimethoprim
-
50% inhibition at 0.027 mM, recombinant rat-derived enzyme, 50% inhibition at 0.0032 mM, recombinant human-derived enzyme
trimethoprim
-
use in yeast protein fragment complementation assay system to prevent endogenous dihydrofolate reductase activity
trimethoprim
-
IC50 value around 0.01 mM
trimethoprim
-
IC50 value around 0.07 mM
trimethoprim
-
-
trimethoprim
Q5CGA3
pH 7.0
trimethoprim
Q07422
pH 7.0
trimethoprim
B5U9U8
-
trimethoprim
-
binding structure, overview
trimethoprim
-
-
trimethoprim
-
-
trimethoprim
Q2YY41
inhibition of the wild-type enzyme, but 74fold less of the resistant mutant F98Y
trimethoprim
-
weak inhibition
trimethoprim
P13955
; conformational changes in the Met20 loop on ligand binding, inhibitor binding thermodynamics, binding structure determined with wild-type and mutant enzymes, crystal structures, single type of independent enzyme binding site, overview
trimethoprim
-
-
trimetrexate
-
recombinant enzyme
trimetrexate
-
-
trimetrexate
-
no increase in inhibitory activity in low-folate medium
trimetrexate
-
-
trimetrexate
-
-
trimetrexate
-
-
trimetrexate
-
-
tylophorinidine
-
plant alkaloid
-
Urea
-
inactivation
Urea
-
3 M, 15% inhibition
Urea
-
-
Urea
-
recombinant enzyme, above 4 M
Urea
-
at concentration 3-4 M complete inactivation
WR99210
Q00NX3
-
WR99210
-
docking analysis, overview
WR99210
-
and PS-15 W99210 prodrug. Active site binding structure of wild-type enzyme, and mutants C59R/S108N and A16V/N51I/C59R/S108N, overview
[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-yl]ethyl)amino]acetic acid
-
-
[amino-(4-[[(amino-thioureido-methyl)-amino]-methyl]-2,5-dimethyl-benzylamino)-methyl]-thiourea
-
IC50: 109 nM, 0.03 mM 7,8-dihydrofolate
additional information
-
overview; stereochemistry of inhibitor binding
-
additional information
-
stereochemistry of inhibitor binding
-
additional information
-
-
-
additional information
-
stereochemistry of inhibitor binding
-
additional information
-
-
-
additional information
protozoa
-
stereochemistry of inhibitor binding
-
additional information
-
-
-
additional information
-
stereochemistry of inhibitor binding
-
additional information
Mus musculus, Pigeon
-
overview
-
additional information
-
overview
-
additional information
-
overview: design of inhibitors from X-ray crystal structures
-
additional information
-
no effect of biopterin and dihydrobiopterin at 0.1 mM; overview
-
additional information
-
inhibitory effect increased with the radius of the cations
-
additional information
-
-
-
additional information
-
overview
-
additional information
-
thymidylate synthase activity inhibitors
-
additional information
-
-
-
additional information
-
-
-
additional information
-
overview antifolate inhibitors, especially methotrexate, and sensitivity or resistance in plants
-
additional information
-
binding study of mutant R53M enzyme from methotrexate resistant strain with methotrexate
-
additional information
-
no inhibition with trimethoprim up to 1.38 mM
-
additional information
-
stable in up to 3 M urea; wild-type enzyme is not affected by presence of NaCl or KCl up to a concentration of 0.3 M, while the His-tagged enzyme is affected even at low concentrations
-
additional information
-
in presence of up to 4 M urea, wild-type retains more than 80% of its catalytic activity. Mutant W48Y loses more than 20% of activity in presence of 1 M urea
-
additional information
-
structure-based three-dimensional quantitative structure-activity relationship 3D-QSAR approach to predict the biochemical activity for inhibitors of Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase and comparison with human dihydrofolate reductase. Crystal structures of complexes of the enzyme with eight different inhibitors of the DHFR activity together with the structure in the substrate-free state have been used to validate and refine docking poses of ligands, good agreement between experimental and predicted enzyme inhibition data
-
additional information
-
structure-based three-dimensional quantitative structure-activity relationship 3D-QSAR approach to predict the biochemical activity for inhibitors of Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase. Crystal structures of complexes of the enzyme with eight different inhibitors of the DHFR activity together with the structure in the substrate-free state have been used to validate and refine docking poses of ligands, good agreement between experimental and predicted enzyme inhibition data
-
additional information
-
inhibitor synthesis and molecular modelling
-
additional information
-
molecular docking of 2,4-diamino-5-methyl-5-deazapteridine derivatives as inhibitors to human DHFR, drug-receptor interaction study, method development and evaluation, overview
-
additional information
-
synthesis and evaluation of 2,4-diaminofuro[2,3-d]pyrimidine inhibitors, overview
-
additional information
Q6FPH0
inhibitor design, structure-activity relationships of the antifolates: methyl groups at the meta and para positions of the distal phenyl ring achieve the greatest number of interactions with the pathogenic enzyme and the greatest degree of selectivity over the human enzyme, antifungal activity can be tuned with substitution patterns at the propargyl and para-phenyl positions, overview
-
additional information
-
design and development of enzyme inhibitors based on on the bioactive conformation of WR99210 extracted from the X-ray crystal structure of quadruple mutant parasite DHFR enzyme, virtual screening and molecular docking, overview
-
additional information
-
inhibitory potencies of diverse 2,4-pteridinediamine derivates and pyrimido[4,5-d]pyrimidine-2,4-diamine derivates, molecular dynamic simulations, detailed overview
-
additional information
-
inhibitor design and synthesis, overview
-
additional information
-
inhibitor design and synthesis, computational modeling, analysis of the interactions of the biphenyl compounds with the enzyme, and drug selectivity in comparison to the human enzyme, overview
-
additional information
-
inhibitor design based on a trimethoprim-like scaffold, overview
-
additional information
Q2YY41
structure based inhibitor development of propargyl derivatives of trimethoprim for inhibition of resistant enzyme, overview
-
additional information
-
the enzyme from Bacillus anthracis is naturally resistant to trimethoprim, at least in part due to the presence of a Phe96 substitution in the putative trimethoprim binding site of the enzyme. Inhibitor development by virtual screening for dual-site inhibitors, overview
-
additional information
-
inhibitor development, molecular docking, modelling, pharmacophore mapping, and three-dimensional quantitative structure-activity relationship studies, 3D-QSAR, studies using the crystal structure, PDB ID 1DF7, determination of structure-functional requirements for the binding of the DHFR inhibitors, overview
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Cl-
-
a few bacterial and vertebrate enzymes are activated at concentrations of 0.3-0.5 M
dithiothreitol
-
-
guanidinium hydrochloride
-
recombinant enzyme, 2.5fold activation at 0.5 M
KCl
-
3.5fold activiation at 0.5 M
KCl
-
3 to 5fold increase in activity
KCl
-
recombinant enzyme, concentration 0.1 M
KCl
-
hDHFR-2, activation is maximal at 0.5 M
KCl
-
2.5-3fold increase in activity at 0.1 M
KCl
-
recombinant enzyme, 1.4fold activation at 40-200 mM
NaCl
-
2.5-3fold increase in activity at 0.1 M
NaCl
-
recombinant enzyme, 1.4fold activation at 40-200 mM
NaCl
-
up to 20% increase in activity up to 0.2 M, activity declines above and falls to zero at 0.8 M
NH4+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild type enzyme activity above 0.1 mM
p-chloromercuribenzoate
-
activates in presence of NADPH
p-chloromercuribenzoate
-
-
p-hydroxymercuribenzoate
-
-
Thiourea
-
-
Urea
-
increase in Km and kcat values for 7,8-dihydrofolate and NADPH
Urea
-
slight activation
Urea
-
activates at 1 M
Urea
-
slight activation
Urea
-
recombinant enzyme, 4fold activation at 3 M
Urea
-
activates at 2 M about 1.5fold
Urea
-
stimulates 1.5fold at 0.75-1.5 M
Urea
-
recombinant enzyme, 7 M
additional information
-
no activation by NaCl, Na2SO4, MgCl2, Li2SO4, CaCl2, MgSO4
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0034
6-Hydroxymethylpterin
-
-
0.00004
7,8-dihydrofolate
P17719
mutant Q134K, pH 8.5, 25C
0.000075
7,8-dihydrofolate
-
wild-type, pH 7.6, 23C
0.00015
7,8-dihydrofolate
-
with NADPH
0.00018
7,8-dihydrofolate
-
pH 7.4, 37C, mutant N64S
0.0003
7,8-dihydrofolate
-
recombinant enzyme
0.0003
7,8-dihydrofolate
-
pH 7.4, 37C
0.00039
7,8-dihydrofolate
-
recombinant enzyme
0.00044
7,8-dihydrofolate
-
-
0.00047
7,8-dihydrofolate
-
-
0.00048
7,8-dihydrofolate
-
recombinant enzyme
0.00049
7,8-dihydrofolate
-
pH 7.4, 37C, mutant Q35K/N64F
0.0006
7,8-dihydrofolate
-
recombinant bifunctional enzyme
0.00061
7,8-dihydrofolate
-
mutant M42I, pH 7.0, 25C
0.00068
7,8-dihydrofolate
-
pH 7.0, 30C, mutant L32F
0.00069
7,8-dihydrofolate
-
mutant F31R/Q35E, pH 7.6, 23C
0.0007
7,8-dihydrofolate
-
pH 7.0, 30C, wild-type
0.0007
7,8-dihydrofolate
-
mutant enzyme R44H, at 15C, pH not specified in the publication
0.0007
7,8-dihydrofolate
-
at pH 7.0 and 20C
0.00074
7,8-dihydrofolate
-
-
0.00076
7,8-dihydrofolate
-
pH 7.4, 37C, mutant Q35K
0.00078
7,8-dihydrofolate
-
pH 7.0, 30C, mutant V76A
0.0008
7,8-dihydrofolate
-
mutant enzyme R44V, at 15C, pH not specified in the publication
0.0008
7,8-dihydrofolate
-
deletion mutant DELTAAla145, at pH 7.0 and 25C
0.00081
7,8-dihydrofolate
-
pH 7.4, 37C, mutant N64F
0.00082
7,8-dihydrofolate
-
mutant M42T, pH 7.0, 25C
0.00083
7,8-dihydrofolate
-
mutant M42P, pH 7.0, 25C
0.00091
7,8-dihydrofolate
-
mutant M42V, pH 7.0, 25C
0.00096
7,8-dihydrofolate
-
pH 7.0, 30C, mutant L32A
0.00097
7,8-dihydrofolate
-
wild-type enzyme from plasmid
0.001
7,8-dihydrofolate
-
mutant enzyme R44Y, at 15C, pH not specified in the publication
0.0011
7,8-dihydrofolate
-
-
0.0011
7,8-dihydrofolate
-
pH 7.4, 37C, mutant Q35S
0.0011
7,8-dihydrofolate
-
mutant enzyme R44C, at 15C, pH not specified in the publication
0.00112
7,8-dihydrofolate
-
mutant M42L, pH 7.0, 25C
0.00118
7,8-dihydrofolate
-
mutant M42G, pH 7.0, 25C
0.00119
7,8-dihydrofolate
P17719
wild-type, pH 8.5, 25C
0.0012
7,8-dihydrofolate
-
mutant C85A/C152S, 15C, pH 7.0; mutant M1P/C85A/C152S, 15C, pH 7.0; wild-type, 15C, pH 7.0
0.0012
7,8-dihydrofolate
-
wild-type, 15C, pH 7.0
0.00123
7,8-dihydrofolate
-
mutant L92M from plasmid
0.0013
7,8-dihydrofolate
-
wild-type enzyme
0.0013
7,8-dihydrofolate
-
wild-type, pH 7.5, 37C
0.0013
7,8-dihydrofolate
-
mutant M42A, pH 7.0, 25C; wild-type, pH 7.0, 25C
0.0013
7,8-dihydrofolate
-
mutant M1A/C85A/C152S, 15C, pH 7.0
0.0013
7,8-dihydrofolate
-
wild type enzyme, at pH 7.0 and 25C
0.0014
7,8-dihydrofolate
-
mutant enzyme R44L, at 15C, pH not specified in the publication
0.0015
7,8-dihydrofolate
-
-
0.0015
7,8-dihydrofolate
-
mutant F31P, pH 7.6, 23C
0.0015
7,8-dihydrofolate
-
mutant enzyme R44G, at 15C, pH not specified in the publication
0.0016
7,8-dihydrofolate
-
mutant R53M enzyme
0.0016
7,8-dihydrofolate
B5U9U8
25C, recombinant GST-tagged enzyme
0.0016
7,8-dihydrofolate
-
pH 7.4, 37C, mutant Q35S/N64S
0.0016
7,8-dihydrofolate
-
mutant enzyme R44A, at 15C, pH not specified in the publication; wild type enzyme, at 15C, pH not specified in the publication
0.0016
7,8-dihydrofolate
-
with NADH as cosubstrate, at 25C and 100 mM HEPES, pH 7.5
0.00167
7,8-dihydrofolate
-
double mutant L16M/L20M from plasmid
0.0017
7,8-dihydrofolate
-
mutant F31G/Q35N, pH 7.6, 23C; mutant F31R/F34T/Q35S, pH 7.6, 23C
0.00171
7,8-dihydrofolate
-
mutant L42M from plasmid
0.00178
7,8-dihydrofolate
-
mutant M42Y, pH 7.0, 25C
0.0018
7,8-dihydrofolate
-
25C, pH 7.4
0.0019
7,8-dihydrofolate
-
pH 7.0, 30C, mutant D31E
0.0019
7,8-dihydrofolate
-
mutant enzyme R44E, at 15C, pH not specified in the publication
0.00193
7,8-dihydrofolate
-
mutant M42H, pH 7.0, 25C
0.00194
7,8-dihydrofolate
-
mutant M42C, pH 7.0, 25C
0.002
7,8-dihydrofolate
-
-
0.002
7,8-dihydrofolate
-
His-tagged human-derived enzyme, pH 7.65
0.002
7,8-dihydrofolate
-
mutant F31R/F34T/Q35R, pH 7.6, 23C
0.0021
7,8-dihydrofolate
-
pH 7.0, 30C, mutant D31N
0.0021
7,8-dihydrofolate
-
mutant F31P/Q35H, pH 7.6, 23C
0.0021
7,8-dihydrofolate
-
mutant enzyme R44I, at 15C, pH not specified in the publication
0.0022
7,8-dihydrofolate
-
mutant F31R/F34A/Q35N, pH 7.6, 23C
0.00222
7,8-dihydrofolate
-
mutant L16M from plasmid
0.00227
7,8-dihydrofolate
-
mutant M42Q, pH 7.0, 25C; mutant M42S, pH 7.0, 25C
0.0023
7,8-dihydrofolate
-
-
0.0023
7,8-dihydrofolate
-
recombinant enzyme, pH 7.0, 0.1 M imidazole
0.0023
7,8-dihydrofolate
-
pH 7.0, 30C, mutant D31Q
0.0023
7,8-dihydrofolate
-
mutant enzyme R44M, at 15C, pH not specified in the publication
0.0024
7,8-dihydrofolate
-
native enzyme
0.0024
7,8-dihydrofolate
-
mutant enzyme R44Q, at 15C, pH not specified in the publication
0.0025
7,8-dihydrofolate
-
mutant M1S/C85A/C152S, 15C, pH 7.0
0.0025
7,8-dihydrofolate
-
mutant enzyme R44K, at 15C, pH not specified in the publication; mutant enzyme R44N, at 15C, pH not specified in the publication; mutant enzyme R44T, at 15C, pH not specified in the publication
0.00268
7,8-dihydrofolate
-
-
0.0027
7,8-dihydrofolate
-
recombinant from E. coli
0.0027
7,8-dihydrofolate
-
mutant F31P/Q35E, pH 7.6, 23C
0.0027
7,8-dihydrofolate
-
pH 7.4, 37C, wild-type enzyme
0.0027
7,8-dihydrofolate
-
pH 7.4, 37C
0.0027
7,8-dihydrofolate
-
mutant enzyme R44F, at 15C, pH not specified in the publication
0.0028
7,8-dihydrofolate
-
pH 7.3, 37C
0.0028
7,8-dihydrofolate
-
pH 7.4, 37C, wild-type enzyme
0.00289
7,8-dihydrofolate
-
mutant L20M from plasmid
0.0029
7,8-dihydrofolate
-
His-tagged enzyme, pH 7.5, 37C; His-tagged recombinant enzyme, pH 7.5, 37C
0.0029
7,8-dihydrofolate
-
mutant enzyme R44P, at 15C, pH not specified in the publication
0.003
7,8-dihydrofolate
-
-
0.003
7,8-dihydrofolate
-
strain PC 174
0.003
7,8-dihydrofolate
-
wild-type enzyme
0.003
7,8-dihydrofolate
-
mutant M1A/M16F/M20L/M42Y/M92F/C85A/C152S, 15C, pH 7.0
0.003
7,8-dihydrofolate
-
mutant enzyme R44D, at 15C, pH not specified in the publication
0.0031
7,8-dihydrofolate
-
mutant enzyme R44S, at 15C, pH not specified in the publication
0.0033
7,8-dihydrofolate
-
mutant F31S/Q35E, pH 7.6, 23C
0.00369
7,8-dihydrofolate
-
triple mutant L16M/L20M/L42M from plasmid
0.0037
7,8-dihydrofolate
-
pH 7.0, 60C
0.0037
7,8-dihydrofolate
-
mutant enzyme R44W, at 15C, pH not specified in the publication
0.0038
7,8-dihydrofolate
-
mutant M1A/M16S/M20L/M42Y/M92F/C85A/C152S, 15C, pH 7.0
0.00385
7,8-dihydrofolate
-
wild type enzyme, in 50 mM TES, pH 7.0, at 37C
0.004
7,8-dihydrofolate
-
-
0.004
7,8-dihydrofolate
-
strain PC 178
0.0042
7,8-dihydrofolate
-
wild-type, pH 5.0, 25C
0.0043
7,8-dihydrofolate
-
mutant F31A/F34V/Q35H, pH 7.6, 23C
0.0045
7,8-dihydrofolate
-
pH 7.3, 37C
0.0047
7,8-dihydrofolate
B5U9U8
25C, recombinant detagged enzyme
0.0048
7,8-dihydrofolate
-
-
0.0048
7,8-dihydrofolate
-
deletion mutant DELTAGly67/DELTAAla145, at pH 7.0 and 25C
0.0049
7,8-dihydrofolate
-
mutant Y35G/F37L, pH 5.0, 25C
0.0049
7,8-dihydrofolate
-
pH 7.4, 37C, wild-type enzyme
0.005
7,8-dihydrofolate
-
mutant N51I/C59R/N108T/I164L, pH 7.0
0.0051
7,8-dihydrofolate
-
pH 7.0, 30C, mutant L32D
0.0051
7,8-dihydrofolate
-
wild-type, 25C, pH 7.0
0.0051
7,8-dihydrofolate
-
deletion mutant DELTAGly67, at pH 7.0 and 25C
0.0052
7,8-dihydrofolate
-
mutant N51I/C59R/N108S/I164L, pH 7.0
0.0053
7,8-dihydrofolate
-
mutant K27E, pH 5.0, 25C
0.0055
7,8-dihydrofolate
-
mutant Y35L/F37R, pH 5.0, 25C
0.0056
7,8-dihydrofolate
-
recombinant rat-derived enzyme, pH 7.65
0.0056
7,8-dihydrofolate
-
deletion mutant DELTAGly67/DELTAGly121, at pH 7.0 and 25C
0.00592
7,8-dihydrofolate
P17719
mutant L30Q, pH 8.5, 25C
0.00597
7,8-dihydrofolate
-
mutant M42E, pH 7.0, 25C
0.0062
7,8-dihydrofolate
-
-
0.0062
7,8-dihydrofolate
-
mutant linear ANLYF-G6, 15C, pH 7.0
0.007
7,8-dihydrofolate
-
mutant V115C, pH 7.6, 23C
0.0073
7,8-dihydrofolate
-
deletion mutant DELTAGly121/DELTAAla145, at pH 7.0 and 25C
0.0076
7,8-dihydrofolate
-
mutant Y35Q/F37R, pH 5.0, 25C
0.0081
7,8-dihydrofolate
-
mutant N51I/C59R/S108N/I164L/K96N, pH 7.0
0.0083
7,8-dihydrofolate
-
mutant M1A/M16N/M20L/M42Y/M92F/C85A/C152S, 15C, pH 7.0
0.0083
7,8-dihydrofolate
-
mutant I51N/C59R/N108S/I164L, pH 7.0
0.0083
7,8-dihydrofolate
-
mutant M1A/M16N/M20L/M42Y/C85A/M92F/C152S, 15C, pH 7.0
0.0085
7,8-dihydrofolate
-
pH 7.4, 37C, mutant K37Q
0.0086
7,8-dihydrofolate
-
-
0.0086
7,8-dihydrofolate
-
mutant Y35L/F37T, pH 5.0, 25C
0.0086
7,8-dihydrofolate
-
mutant linear ANLYF-G8, 15C, pH 7.0
0.0095
7,8-dihydrofolate
-
pH 6.0
0.0096
7,8-dihydrofolate
-
mutant isoform that carries the K32M mutation in gene copies 1 and 3 and the Q67H mutation in gene copies 2 and 4, pH 7.0, 30C
0.01
7,8-dihydrofolate
-
altered enzyme
0.0106
7,8-dihydrofolate
-
native rat-derived enzyme, pH 7.65
0.0108
7,8-dihydrofolate
-
deletion mutant DELTAGly121, at pH 7.0 and 25C
0.0115
7,8-dihydrofolate
-
mutant circular ANLYF-G6, 15C, pH 7.0
0.013
7,8-dihydrofolate
-
-
0.013
7,8-dihydrofolate
-
recombinant wild-type enzyme
0.013
7,8-dihydrofolate
-
mutant circular ANLYF-G7, 15C, pH 7.0
0.0133
7,8-dihydrofolate
-
mutant N51I/C59R/S108N/I164L, pH 7.0
0.014
7,8-dihydrofolate
-
recombinant mutants S108T and S108A
0.014
7,8-dihydrofolate
-
mutant carrying the K32M mutation in gene copies 1 and 3 with the Q67H mutation in all gene copies, pH 7.0, 30C
0.014
7,8-dihydrofolate
-
mutant circular ANLYF-G8, 15C, pH 7.0
0.01444
7,8-dihydrofolate
-
mutant enzyme Y102F, at pH 7.0 and 25C
0.0145
7,8-dihydrofolate
-
mutant N51I/C59R/S108N/I164L/D187A, pH 7.0
0.01465
7,8-dihydrofolate
-
mutant N51I/C59R/S108N/I164L/I150V/N182I/N201D, pH 7.0
0.015
7,8-dihydrofolate
-
mutant V115A, pH 7.6, 23C
0.01625
7,8-dihydrofolate
-
mutant enzyme T86S, in 50 mM TES, pH 7.0, at 37C
0.017
7,8-dihydrofolate
-
-
0.0178
7,8-dihydrofolate
-
25C, pH 7.0, pressure 0.1 MPa
0.0195
7,8-dihydrofolate
-
25C, pH 7.0, pressure 200 MPa
0.02 - 0.025
7,8-dihydrofolate
-
recombinant mutants S108G, S108N and S108C
0.0207
7,8-dihydrofolate
-
mutant N51I/C59R/S108N/I164L , pH 8.0, 25C
0.0209
7,8-dihydrofolate
-
mutant N51I/C59R/S108N, pH 8.0, 25C
0.022
7,8-dihydrofolate
-
-
0.0231
7,8-dihydrofolate
-
mutant W48Y, 25C, pH 7.0
0.03051
7,8-dihydrofolate
-
mutant enzyme T86N, in 50 mM TES, pH 7.0, at 37C
0.0324
7,8-dihydrofolate
-
mutant W48Y/N188Y, 25C, pH 7.0
0.0337
7,8-dihydrofolate
-
wild type enzyme, at pH 7.0 and 25C
0.035
7,8-dihydrofolate
-
-
0.036
7,8-dihydrofolate
-
-
0.037
7,8-dihydrofolate
-
pH 7.0, 30C, mutant D31A
0.03825
7,8-dihydrofolate
J7GQW2
at pH 7.0 and 22C
0.0444
7,8-dihydrofolate
-
wild-type, pH 8.0, 25C
0.045
7,8-dihydrofolate
-
mutant M42W, pH 7.0, 25C
0.05
7,8-dihydrofolate
-
recombinant mutant S108Q
0.0502
7,8-dihydrofolate
-
deletion mutant DELTAArg52/DELTAGly67, at pH 7.0 and 25C
0.0512
7,8-dihydrofolate
-
deletion mutant DELTAArg52/DELTAGly121, at pH 7.0 and 25C
0.0777
7,8-dihydrofolate
-
deletion mutant DELTAArg52/DELTAAla145, at pH 7.0 and 25C
0.08
7,8-dihydrofolate
-
lowest Km value in 3.0 M KCl, recombinant wild-type enzyme
0.097
7,8-dihydrofolate
-
mutant enzyme
0.107
7,8-dihydrofolate
-
wild-type enzyme
0.1161
7,8-dihydrofolate
-
deletion mutant DELTAArg52, at pH 7.0 and 25C
0.198
7,8-dihydrofolate
-
pH 7.0, 30C, mutant D31L
0.2301
7,8-dihydrofolate
-
mutant enzyme F96I, at pH 7.0 and 25C
16.4
7,8-dihydrofolate
Q70YQ6
pH 7.0, 20C
19.8
7,8-dihydrofolate
Q70YQ6
pH 7.0, 30C
21.7
7,8-dihydrofolate
Q70YQ6
pH 7.0, 5C
0.03
8-Methylpterin
-
pH 5.0
0.13
8-Methylpterin
-
pH 5.0
0.2
8-Methylpterin
-
pH 7.4
0.3
8-Methylpterin
-
above pH 7.4
0.00063
dihydrofolate
Q54801
mutant H26Y/Q60K/A77V/V78A/Q81H/Q91S/L100V/E133A/A149T, pH 7.0, 25C, value below
0.001
dihydrofolate
-
pH 7.0, 25C, under atmospheric pressure
0.0018
dihydrofolate
D1MX71
pH 7.0, 25C, under atmospheric pressure
0.0019
dihydrofolate
-
pH 7.5, 25C
0.0019
dihydrofolate
D1MYR1
pH 7.0, 25C, under atmospheric pressure
0.004
dihydrofolate
Q54801
wild-type, pH 7.0, 25C
0.0062
dihydrofolate
D1MX70
pH 7.0, 25C, under atmospheric pressure
0.238
dihydrofolate
D1MX72
pH 7.0, 25C, under atmospheric pressure
0.0009
dihydropteroate
-
-
0.0041
folate
-
bifunctional enzyme DHFR-thymidylate synthase
0.006 - 0.007
folate
-
-
0.0067
folate
-
-
0.268
NADH
-
-
0.32
NADH
-
-
0.00043
NADPH
-
25C, pH 7.6
0.00065
NADPH
-
pH 7.0, 30C, mutant D31Q
0.00068
NADPH
-
pH 7.0, 30C, mutant D31A
0.00075
NADPH
Q54801
mutant H26Y/Q60K/A77V/V78A/Q81H/Q91S/L100V/E133A/A149T, pH 7.0, 25C